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PROCESS VALIDATION OF GRISEOFULVIN TABLETS 
 
1. INTRODUCTION 
 
1.1.VALIDATION 
 
Validation is the study of demonstrating and documenting at a manufacturing process 
operates efficiently. 
 
The pharmaceutical process validation refers that it should cover all the critical parameters 
in a manufacturing process for a pharmaceutical dosage form, from designing a process to 
final validation of that the formulation in the large scale production. 
 
Accordingly it is obvious that compliance with the finished product specification itself may 
not be sufficient to assure that the processes are valid and the manufacturer has full control 
over the process. [1] 
 
However, Validation is an essential part of Quality Assurance Program and is fundamental to 
an efficient production operation. [2] 
 
In the Federal Register FDA issued a notice on May 11, 1987 (52 FR 17638), the availability 
of guidelines entitling Guidelines on General Principles of Process Validation (the 1987 
guidance). [3] 
 
FDA has the authority of responsibility to inspect and evaluate process validation performed 
by manufacturers. The cGMP regulations for validating pharmaceutical (drug) manufacturing 
process quotes that drug products be produced requires a high degree of assurance for 
meeting all the predetermined specifications they are intended to meet (21 CFR 211.100(a) 
and 211.110(a)). [3] 
 
Effective process validation leads ultimately to an assured drug quality. The fundamental 
objective of quality assurance is that a product produced should be fit for its intended use. 
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This principle incorporates the understanding that the following conditions exist: [4] 
 
1. Quality, safety, and efficacy are to be designed in the product.  
2. In-process and finished-product inspection or testing is not sufficient to assure the 
quality of the product. 
3. Every step of the process should be controlled for an assured finished product that 
meets all the quality attributes including predetermined specifications.  
 
1.2.DEFINITIONS 
 
EUROPEAN COMMISSION (E.C) 
1991 - “Validation: Act of proving, in accordance of GMPs that any manufacturing Process 
actually leads to expected results”. [1] 
 
USFDA 1987 
US Food and Drug Administration, 1987 “Process Validation is establishing documented 
evidence which provides a high degree of assurance that a specified process will consistently 
produce a product meeting its pre established limits and quality attributes.” [3] 
 
USFDA 2011 
Process validation is defined as the collection and evaluation of data, from the process design 
stage through commercial production, which establishes scientific evidence that a process is 
able to produce a product with high quality constantly. [4] 
 
WORLD HEALTH ORGANISATION (W.H.O) 
“Action of providing that any procedure, process, equipment, material, activity, or system 
actually leads to the expected results.” [5], 
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1.3.REASON FOR PERFORMING PROCESS VALIDATION 
 
The principle goal for validation is to assure, completely, that all the manufacturing 
processes, procedures and machinery being used should ensure safety, quality and strength of 
that formulation. Validation is very eminent, if there are any prominent changes to the 
premises, the facilities, the process or the equipment which may interferes with the quality of 
that product, directly or indirectly, partially or fully, should be validated. [6] 
 
A process should also be validated to meet regulatory requirements. The Regulatory bodies, 
such as the FDA, shall need process validation. The US-FDA Quality System Regulation 
requires manufacturers to perform validation when the process is not completely verified by 
an appropriate inspection or test. [7] 
 
A properly and completely validated, controlled process results in little scrap or re- 
processing, leads an increased output. Consistent compliance to specifications also results in 
fewer complaints and recalls. Whenever needed, the validation document contains the data to 
assist any improvements in a process or in the design of the next generation of the process. [8] 
 
1.4.STAGES AND GENERAL PRINCIPLE TO PROCESS VALIDATION [5] 
 
Process validation includes a series of activities taking place throughout the outcome of the 
product. They are: 
 
 Stage 1 – Process Design: The commercial manufacturing process is defined during 
this stage are in accordance with the development and scale-up activities.  
 
 Stage 2 – Process Qualification: In this stage, the process design is evaluated to 
determine, whether the process is capable of reproducible commercial manufacturing.  
 
 Stage 3 – Continued Process Verification: Further assurance is attained during regular 
production that the process remains in a state of control.  
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1.4.1. Process Design: Stage 1 
This is the step where building and capturing of the process knowledge and understanding 
took place. Process Design includes Research and development(R&D), formulation design, 
pilot plant scale-up techniques, TTG for commercial manufacturing of batches, determining 
stability parameters & storage conditions, handling of in-process quality assurance and 
finished forms of product, equipment, operational and installation qualification, master 
documents and process capacity.  
 
1.4.2. Process Qualification: Stage 2 
This stage is confirmation that the process design is capable of reproducing the 
manufacturing process. It confirms that all pre determined limits of the Critical Process 
Parameters are valid and that quality products can be produced even under “worst case” 
conditions. GMP compliant procedures must be followed in this stage and successful 
completion of this stage is necessary before marketing of a product. 
 
1.4.3. Continued Process Verification: Stage 3 
The Validation Maintenance Stage requires a frequent review of all process related 
documents, including validation audit reports to assure that there have been no changes, 
deviations, failures; changes if any in the manufacturing process, Standard operating 
procedures are employed, in addition to change control procedures.  
 
Before commercial distribution of any batch, the manufacturer should have complete 
assurance of process performance. A proper understanding, knowledge and approach to 
production process may lead to a successful validation of a product. 
 
1.5. CONCEPT OF VALIDATION [9] 
The concept of validation is to ensure a steady production of a quality product throughout its 
life cycle that includes the critical aspects of ICH Q8, Q9 and Q10 guidelines. It makes sure 
that the process, equipment, materials and finished product produce a product having quality 
and purity as per the patient/customer requirements. Both FDA and cGMP states that control 
procedure shall be established to monitor output and to validate the performance of those 
manufacturing process that may be responsible for causing variability in the characteristics of 
in process materials and drug materials. 
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 1.6 SCOPE OF PROCESS VALIDATION 
 
Process validation acts as a tool for the pharmaceutical manufacturing companies to ensure 
the manufacturing process including instruments and facilities are in a state of control and 
also to provide evidence that the final product meets the quality, purity and integrity as 
specified. 
 
 1.7. TYPES OF PROCESS VALIDATION [10] 
 
The four types of process validation are: 
1.7.1. Prospective Validation 
 
In Prospective Validation, the validation protocol is implemented before the manufacturing 
process is put into commercial use. During the product development phase the manufacturing 
process should be divided into individual steps. Each step should be evaluated on the basis of 
experience or theoretical considerations to establish the critical parameters that may alter the 
quality of the finished product. A series of experiments should be designed to determine the 
cruciality of these factors. Each experiment should be planned and documented in an 
authorised protocol. 
 
All equipment, production atmosphere and the analytical testing procedures and methods to 
be used should have been fully validated. Master batch documents can be prepared only after 
the critical parameters of the manufacturing process have been identified and machine 
settings, component specifications and environmental conditions have been pre-determined. 
 
It is generally taken acceptable that three consecutive batches/runs within the finally agreed 
parameters, giving product of the desired quality with a proper validation of the process. It is 
an assurance on the commercial three batches before marketing. 
 
After completion of the review, the recommendations should be made on the extent of 
monitoring and the in-process controls needed for routine production. These should be 
included into the batch manufacturing and packaging record or into appropriate Sops. The 
deviations if any must be specified and appropriate steps to be taken in case of exceeding 
limits and frequencies. 
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1.7.2. Concurrent Validation 
 
Concurrent validation may be the practical approach under certain circumstances. 
Examples such as when: 
 
1. A previously validated process is being transferred to a third party contract 
manufacturer or to another manufacturing site. 
2. The product is a different strength of a previously validated product with the same 
ratio of active/inactive ingredients. 
3. The number of lots evaluated under the Retrospective Validation were not sufficient 
to obtain a high degree of assurance demonstrating that the process is fully under 
control 
4. The number of batches produced is limited (e.g. orphan drugs). 
5. Process with low production volume per batch (e.g. radiopharmaceuticals, anticancer) 
6. Process of manufacturing urgently needed drugs due to shortage (or absence) of 
supply. 
 
 The proper cause and reason to perform validation should be evidenced by document. 
And the Validation Team must approve the validation protocol. A summary report must be 
made and approved before marketing of any batch. After completing approval for all 
commercial batches a final report is established. It is usually said, acceptable that a minimum 
of three consecutive batches within the specification limits and with desired quality will lead 
to a complete validation study. 
 
1.7.3. Retrospective Validation 
 
In many establishments, the processes that are stable and in regular use have not undergone a 
formally documented validation process. Historical data may be used to provide necessary 
documentary evidence that the processes are validated. The steps involved in this type of 
validation need the preparation of a protocol, the reporting of the results of the data review, 
leading to a conclusion and Recommendation. Retrospective Validation stage possesses flow 
charts of process, BMR, In-process & finished product test results with trends and stability 
studies, premises, maintenance and equipment/instrument log books. 
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In retrospective validation studies, it is generally considered acceptable that data from a 
minimum of ten consecutive batches produced be utilized. When less than ten batches are 
available, it is considered that the data is not enough to demonstrate retrospectively that the 
process is fully under control. In such cases the study should be added with data generated 
with concurrent or prospective validation. 
 
Some of the basic aspects of Retrospective Validation are 
• Batches done for a determined duration (minimum of 10 last consecutive batches). 
• Number of batches marketed per annum. 
• Batch size, strength, manufacturer, time period. 
• BMR/BPR (manufacturing & packing records). 
 
1.7.4. PROCESS RE-VALIDATION  
Re-validation is generally done to confirm the initial validation for a Periodic review. Re-
validation provides the evidence that alterations in a process and /or the process environment 
that are introduced does not adversely affect process Characteristics and product quality. 
Documentation requirements shall be the same as for the initial validation of the process. Re-
validation becomes essential in particular situations. 
  
These are few examples of the modifications which may need re-validation: 
 
1. Changes in raw materials (physical properties such as density, viscosity, particle size 
distribution, and moisture, etc., that interferes with the quality of a process or 
product). 
2. Changes in the source of active raw material manufacturer. 
3. Changes in packaging material (primary container/closure system). 
4. Changes in the process (ex: drying temperatures, time of mixing etc) 
5. Changes in the equipment (ex: addition of automatic detection system). The 
replacement of equipment may normally not require a re-validation unless the new 
equipment is approved for qualification. 
6. Changes in the plant/facility.  
7. Variations revealed by trend analysis (e.g. process drifts). 
A decision not to perform re-validation studies must be fully justified and documented. 
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1.8. CHANGE CONTROL 
 
Clearly defined procedure is needed to control any changes in the manufacturing processes. 
These procedures must control all the planned changes and ensure the presence of adequate 
supporting data which shows that modified manufacturing process will yield a product of 
desired quality.  
 
Significant changes if any, to process (e.g. mixing time, drying temperature, etc.), using new 
equipments with different operating parameters, etc may require the pre-approval. If a change 
is proposed in any of the procedures, product, processes, or equipment, which may affect the 
quality, proper written procedures should be placed.  
 
1.9. IMPORTANCE OF PROCESS VALIDATION [6] 
 
1. Compliance to Regulatory bodies 
2. Assurance in quality 
3. Optimization in the process 
4. Reduced cost of production  
5. Reduction in Batch failures, enhancement in efficiency and productivity 
6. Lowering down time 
7. Reduced rejections 
8. Increased output 
9. Minimum complaints about process–related failures. 
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1.10. PROCESS VALIDATION PROTOCOL (IH) 
TABLE: NO. 1 
S.No Process validation protocol 
1 Objective 
2 Lable claim 
3 Validation team and responsibility 
4 Scope of the protocol 
5 Manufacturing formula 
6  process flow chart 
7 Rationale for selection of critical steps and its process parameters for validation 
8 Critical steps, variables to be studied, measured response & acceptance criteria 
9 Prerequisites for process validation 
10 Yield details 
11 General tests of raw material/packing material  
14 List and qualification of equipments/instruments 
15 Manufacturing and sampling procedures at different stages of process validation 
  1. Sifting 
  2. Dry mixing  
  3. Sampling point diagram of rmg  
  4. Granulation 
  5. Drying  
  6. Sampling point diagram of fbd  
  7. Blending  
  8. Sampling point diagram of blender 
  9. Compression  
  10. Coating  
  11. Sampling point diagram of coating pan 
  12. Dissolution profile 
  13. Packing  
  14. Stability studies 
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16 Process validation report 
  1. Test results for raw materials 
  2. Dry mixing 
  3. Granulation 
  4. Drying 
  5. Blending 
  6. Compression 
  7. Coating 
  8. Dissolution profile 
  9. Blister packing 
  10. Yield details 
  11. Finished product report 
  12. Stability report 
17 Discussion 
18 Future scope 
 
 
1.11. REGULATORY REQUIREMENTS FOR THE PROCESS VALIDATION [5] 
 
Process validation for drugs (finished pharmaceuticals and components) is a legally 
enforceable necessity under section 501(a) (2) (B) of the Act (21 U.S.C. 351(a)(2)(B)), gives 
about:  
 
 A drug shall be said to be adulterated if, the procedures used in, or the facilities or 
controls used for, its manufacture, processing, packing, or holding do not conform to or are 
not operated or administered in conformity with current GMP to assure that such drug meets 
the requirements of this Act as to safety and has the identity and strength, and meets the 
quality and purity characteristics, which it is intended to possess. 
 
The cGMP regulations needs that manufacturing processes be framed and controlled to 
establish that in-process materials and the finished product meets the predetermined quality 
attributes, consistently and reliably. 
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1.12. HISTORY OF PROCESS VALIDATION 4, 11 
 
The emphasis on validation began in the late 1970s; the necessity has been around since at 
least the 1963 cGMP regulations for finished products.  
 
The Kefauver-Harris Amendments to the FD&C Act were approved in 1962 with Section 
501(a) (2)(B) as an amendment. Before that, cGMP, validation is not mandatory by law. The 
FDA had the hurdle of assuring that a drug was adulterated by collecting and analyzing 
samples.  
 
This was a great regulatory burden and restricted the value of factory inspections of 
pharmaceutical manufacturers. The Kefauver–Harris amendments result was that the Federal 
Drug Administration need to declare a drug product is adulterated, if the manufacturing 
process was not validated. 
 
Section 505(d)(3) is also significant in the implementation of process validation requirements 
as it gives the authority to withhold approval of a new drug application if the “methods used 
in, and the facilities and controls used for, the manufacture, processing, and packing of such 
drug are not sufficient to record that drug’s strength, quality, identity and purity. 
 
1.13. MASTER MANUFACTURING DOCUMENT 
 
An eminent prospective validation program must be assisted by documentation extending 
from product initiation to full-scale production. A complete documentation can be referred to 
as the master documentation file. It provides a full product history that is being produced. 
The master documentation file must contain all information that was generated during the 
entire product development sequence to a validation process. [10] 
 
The documents should be checked for data accuracy and adequacy as required by the FDA’s 
guidelines.  
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Documentation covers the items, which should be compiled in a timely manner, are: [12] 
1. Process challenging and characterization reports that contain a full description of the 
studies performed 
2. Development batch record 
3. Raw material test methods and specifications 
4. Equipment list and qualification and calibration status 
5. Process flow diagram 
6. Process variable tolerances 
7. Operating instructions for equipment (where necessary) 
8. In-process quality control program, including: 
a. Sampling intervals 
b. Test methods 
c. Finished Product 
d. Stability 
9. Critical unit operation 
10. Final product specifications 
11. Safety evaluation 
12. Chemical 
13. Process 
14. Special production facility requirements 
15. Cleaning 
a. Procedure for equipment and facilities 
b. Test methods 
16. Stability profile of the product 
17. Produced during process development 
18. Primary packaging specification 
 
A report is prepared which cross – refers the validation protocol, and that summarizes the 
obtained results, explores deviations (if any), draws conclusions that includes recommending 
changes to correct the deviations. Any change to the plan as mentioned in the protocol must 
get documented with appropriate justification. [13] 
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1.14. VALIDATION MASTER PLAN: [14] 
 
A validation master plan is a document that concludes the company’s overall history, 
intentions goals and approaches to be used for establishing performance adequacy. The 
Validation Master Plan should be accepted by management. 
 
Validation in general requires a serious preparation and keen planning of the various stages in 
the manufacturing process. In addition, all work should be carried out in a planned way as per 
formally authorised Sops. All observations must be documented and where possible results 
must be recorded as actual numerical results.  
 
The validation master plan should give an overview of the complete validation program, its 
organizational structure, its contents and plans. The principle components of it are the 
list/inventory of the items to be validated and the planning schedule.  
 
All validation activities relating to critical technical operations, related to product and 
manufacturing process controls within an organisation must be incorporated in the validation 
master plan. It may refer to existing documents such as policy documents, SOP’s and 
validation protocols and reports, but it must not repeat information documented anywhere.  
 
The format should contain: 
 
1. BMR 
2. Master formula 
3. Flow charts of the process 
4. Master manufacturing and packaging guidelines 
5. Specifications 
6. Sampling (point of location and number) 
7. Methods for performing tests 
8.  validation data of the process 
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1.15. STAGES AND PARAMETERS PERFORMED DURING PROCESS 
VALIDATION 
TABLE: NO. 2 
Stage Process variables Tests performed 
Dry mixing Mixing time 
Uniformity of content, Bulk density, moisture content, 
sieve analysis 
Granulation 
Mixing time impeller 
reading during mixing 
  
Drying 
Inlet & outlet 
temperature drying time 
Final drying, Loss on drying/moisture content 
Blending 
  
Blending time 
  
Uniformity of content & RSD 
Bulk density, sieve analysis & compressibility index 
Compression Pre compression studies Optimum speed-Dissolution at lower & higher thickness 
Compression 
Machine speed (10 - 30 
rpm) 
At different speeds 
Appearance  
Group weight variation 
Individual weight variation 
Thickness 
Hardness 
Friability 
Disintegration time 
Dissolution  
Content uniformity 
Assay 
Compression 
Hopper study at 
maximum speed 
Full hopper, middle of hopper & near end of hopper 
Individual weight variation 
Thickness 
Hardness 
Friability 
Disintegration time 
Content uniformity 
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Coating 
Inlet temp. Exhaust temp. Pan 
speed atomization pressure, 
spray rate gun distance 
Weight build up 
At the end of coating 
LOD 
Dissolution profile at 15, 20, 30, 45 & 60 
minutes 
Blister packing 
Machine speed, forming and 
sealing temperature 
Blister appearance and quality, leak test and 
impurity 
 
1.17. BATCHES STUDIED FOR PROCESS VALIDATION 
 
A. BATHCES FOR RAW MATERIALS 
 
PVG01- Process Validation of Griseofulvin Tablets 
PVG02- Process Validation of Griseofulvin Tablets  
PVG03- Process Validation of Griseofulvin Tablets 
 
B. BATHCES FOR FINISHED PRODUCT 
 
GRIS01- Griseofulvin Tablets 
GRIS02- Griseofulvin Tablets 
GRIS03- Griseofulvin Tablets 
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2. AIM AND OBJECTIVE 
• The present study is “Process Validation of Griseofulvin”. 
• The company is involved in the manufacturing and distribution of a wide range of 
Pharmaceutical products. 
• The present study “Process Validation of Griseofulvin 375 mg Tablets”, is designed 
in meeting the US-FDA requirements to scientifically prove that the finished product 
meet its predetermined specifications and Quality attributes.  
• The major objective of the study is to systemically conduct the validation studies 
pertaining to the manufacturing activities of Griseofulvin 375 mg Tablets. 
• A validation protocol is established and based on that each stage of manufacturing 
process is to be monitored. Three consecutive batches of Griseofulvin should be 
validated. 
• Samples are to be collected from respective stages and appropriate tests are to be 
carried out depending on the validation protocol. Results of all the tests are to be 
recorded, compared and based on that documentary evidence should be established to 
confirm that the manufacturing process of Griseofulvin consistently meet its 
predetermined specifications and Quality attributes. 
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3. REVIEW OF LITERATURE 
 
Singh , et al., 2012 validation is a comprehensive programme within the industry to 
achieve a quality product. The multidisciplinary validation team must confirm the process 
characteristics and specific validation test for a product to ensure that all the quality 
parameters were achieved. Scientific information obtained during preformulation forms 
the basis for comprehensive validation process.15 
 
Chawla N.S. et al., 2012 gave an overview on the role of Process Validation in Tablet 
manufacturing process. They have notified that the validation as a documented act which 
demonstrates whether a procedure, process, activity etc., gives consistently the expected 
results or not. They highlighted that the Process Validation is a must for any 
manufacturing process, because testing a sample of a final product is not considered 
sufficient evidence to demonstrate that every product meets its specifications. The data 
obtained from the results of three consecutive batches of tablets are essential for 
concluding a Process Validation.16 
 
Parnitha.K, et al., 2012 have discussed about tablet manufacturing process including 
Pre/Post approval issues as per USFDA guidelines. The objective of their study is to 
document each stage of manufacturing process giving importance to validation and 
evaluation of pharmaceutical dosage forms. It also includes guidelines about some 
equipments such as Blenders, Dryers, Tablets and Capsule equipments, Coating 
equipment etc.17 
 
Pandit D., Mishra A., 2011 Pharmaceutical validation guarantees the reliability and 
reproducibility of the manufacturing process. The article examines the need for 
pharmaceutical validation, the various approaches, processing stage and control variables 
and sampling plan related to tablets dosage form to scientifically prove that the process 
produces a quality product.18 
 
Sunil.K.D., et al., 2011 In this study they have stated the process control is a major 
requirement of cGMP regulation for finished pharmaceutical products. It acts as a key 
element in acquiring quality of a product. They also specified the importance of process 
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validation as an integral part of process control. Process control is essential part in the 
quality assurance of pharmaceutical product.19 
 
Bodavula S.S.R. el al., 2011 have studied process validation of fluconazole. According 
to his study CGMP and U.S. FDA’s guidelines demands written procedures for 
production and process controls to assure that the drug products have the identity, 
strength, quality and purity. He has performed the validation study on bulk and finished 
product of fluconazole. He has also performed the pharmacokinetic studies in his 
research.20 
 
Sharad K. et al., 2011 have done process validation of Azifast 500mg tablets. They says 
that the validation is a fundamental concept of GMP’s and quality assurance programme. 
They have performed the validation programme for Azifast tablets in various critical 
stages and concluded that the results are in the state of control based on the analytical 
report.21 
 
Pravin P. et al., 2011 has done research on the prospective process validation of 
Gliclazide tablet 80mg sold dosage formulation. The critical process parameters were 
identified with the help of optimization batches. The critical parameters involved in 
sifting, dry mixing, granulation, dry mixing, lubrication and compression stages were 
identified and evaluated. The report of the study concludes that validation data provides 
high degree of assurance that manufacturing process product meeting its predetermined 
specifications and quality attributes.22 
 
Vandana B.P. et al., 2011 have studied prospective process validation of cimetidine 400 
mg tablet dosage form. She has studied the critical process parameters including raw 
material specifications, packing material specifications, various stages of granulation and 
compression, dissolution studies for finished products. The report of the study conducted 
on three batches have concluded that validation of process delivers a quality products that 
meets the specifications.23 
 
Kanakadurga D.N., Mrudula B.S., et al., 2010 have performed process validation of 
galantamine hydrobromide tablets where they have performed the validation of critical 
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steps during manufacturing as per validation protocol. They have monitored the 
environmental conditions during every step of manufacturing for all the three batches.24 
 
Rohokale BS., et al., 2010 has studied the process development of nimusulide 100mg 
tablet. They have concluded three batches of nimusulide 100mg to confirm that the 
production process was robust and rugged. They have concluded that process is feasible 
in the pilot scale production.25 
 
Venkataraveendranath T. et al., 2010 have performed the process validation of 
Citalopram hydrobromide tablets. They have mentioned the importance of process 
validation in the pharmaceutical manufacturing. The purpose of the study is to determine 
the validation of process, Qualification of equipment and Inprocess study to conclude that 
the control over the critical parameters in the production of tablets leads to finished 
product with quality and purity what the product suppose to contain.26 
 
Bharathi R., 2010 has been found that validation concept is important essential tools for 
Quality Management in Pharmaceutical Industry. It provides verification and validation 
of manufacturing process. Validation consists of a series of activities which includes 
documenting the process data and also confirming that a quality product can be 
manufactured by the designed the processes. Validation is an evidence to confirm that the 
process is in a state of control.27 
 
Raghunandanan R., 2009 has provides an information on Validation Aspect of Solid 
Dosage Form. They have discussed the complete picture regarding validation of a solid 
dosage form in the given facilities and process. Validation is not only a regulatory 
requirement but also firm essential. Benefits of validation include reduction in cost, 
elimination of number of rejections and reprocessing of manufactured batches, improves 
the yield and consistent quality maintenance.28 
 
Westerhuis et al.2006 developed simple assessment of homogeneity in pharmaceutical 
mixing processes. Establishment of uniform mixing of active pharmaceutical ingredient 
(API) with excipients is a crucial in-process quality control in the manufacturing of solid 
dosage forms.29 
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Sharareh S.B., et al.2005 they have discussed the validation of drying process which 
plays a vital role in formation of uniform size granules. Parameters like inlet and outlet 
temperatures, product temperature and LOD are the critical variables In the drying 
process, that could have a possible effect on the quality of a product.30 
 
Aleem Het al., 2003 has discussed about the Drugs which are critical elements in health 
care. All the pharmaceutical products must be manufactured with maximum quality. 
Finished product testing alone is not sufficient to assure the product quality. Quality 
assurance department must ensure the maintenance of product quality. Pharmaceutical 
companies perform the process validation in ensuring that the process functions as what it 
is intended to do.31 
 
O. Okhamafe et al.2002 gave an overview of pharmaceutical validation and process 
controls in drug development. Manufacturing facilities and processes involved in 
pharmaceutical production show its significant impact on the quality of the finished 
products. This process includes raw material specifications and equipment qualifications 
in addition to in-process controls. The intention of validation is to monitor the 
performance of the manufacturing process and conclude it to be validated.32 
 
Brenda M, Wenzel and Brent H.H., 2002 have found that pharmaceutical organizations 
have a training need for validation skills that cover the areas of protocol execution, 
protocol development, validation project management, and documentation control. This 
type of training is useful in the enhancement of knowledge about validation to the 
personnel’s involved in process validation programme.33 
 
Reiner Kirrstetter., 2002 has been found that process validation of Active 
Pharmaceutical Ingredients is most challenging topic. Validation is the essential tool, of 
US-FDA in ensuring the quality of a product and process involved. It includes cleaning 
validation, analytical method validation, computer system validation and equipment 
qualification that could have effect on quality and purity of a product are to be validated. 
The objective of validation study starts from initial product development till completion 
of the product. 34 
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Gamal A. 2000 Has discussed the necessary components required for a successful 
validation programme to obtain a quality product with predefined specifications. He 
discussed the manufacturing of API and using it in the manufacturing of the coated tablet 
dosage forms.35 
 
Robert A.nash et al., 1996 The author takes the reader through the various stages, 
phases, and steps in the product and process development sequence of solid-dosage form 
design (tablet and capsule) using process validation principles and practices. The 
challenge for the pharmaceutical industry as it approaches the next millennium is to 
streamline and/or simplify validation requirements without sacrificing product quality and 
process flexibility.36 
 
Scott B., et al., 1996 has discussed the process validation and its importance in solid 
dosage forms. Process validation is initiated by monitoring and evaluating the process 
performance in order to ensure that the process will consistently deliver a quality product 
throughout its life cycle.37 
 
Maynard D.W 1993 gave the importance of validation master plan in conducting the 
validation programme. The tests to be performed, sampling, Inprocess testing and 
qualification of the equipment plays a major role in the validation study. Documenting the 
results at each stage plays is mandatory as pre USFDA and GMP guidelines.38 
 
Sharpe J.R. et al., 1986 A discussion on process validation as an important element in 
GMP of pharmaceuticals products is presented. The importance of validation is 
exemplified in the production of sterile and non-sterile products.39 
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4. MATERIALS AND METHODS 
Objective 
To establish scientific evidence that the manufacturing process will consistently produce 
Griseofulvin tablets, meeting its predetermined acceptance criteria and consistently deliver 
quality product. 
Lable claim 
Each film coated tablet contains: 
 Griseofulvin IP 375 mg 
Responsibilities 
TABLE: NO. 3  
1 Technology 
Transfer 
To prepare, review & approve the process validation protocol 
report. 
2 Production Execution of manufacturing process during validation. Review 
and approval of process validation protocol and report.  
3 Quality Control To analyze validation samples and review of Analytical report. 
4 Regulatory Affairs To review the protocol and report from Regulatory perspective. 
5 Quality Assurance To monitor the validation activity & sampling as per the 
sampling plan of protocol. Review and approval of process 
validation protocol and report.  
 
Scope of protocol: 
¾ The scope of this protocol is applicable to the validation of manufacturing process of 
Griseofulvin tablets to be carried out. 
¾ If any batch (es) fails due to process extrinsic causes or deviations from the batch 
manufacturing record/protocol the batch (es) will be disqualified for validation 
purpose and fresh three consecutive batches shall be considered for validation. 
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4.1. MANUFACTURING FORMULA 
TABLE: NO. 4 
Granulation and Blending Materials 
S.No Materials Grade Category 
1 Griseofulvin *$ IP Antifungal 
2 Maize Starch ** IP Diluent 
3 Sodium Lauryl sulphate IP Disintegrant 
4 Polyethylene glycol 6000  IP Binding agent 
5 Povidone (PVP K30) IP Binding agent 
6 Purified water  @ IP Vehicle 
7 Sodium Starch glycollate  IP Disintegrant 
8 Talc  IP Glidant 
9 Magnesium stearate  IP Lubricant 
10 Colloidal silicon dioxide  IP Glidant 
11 Maize Starch  IP Disintegrant 
12 Maize Starch ***    (LOD  
compensation) 
IP LOD Compensation 
 
TABLE: NO. 5 
Coating Materials 
S.No COATING MATERIAL Grade CATEGORY 
1 Hypromellose 5cps USP Coating agent 
2 Dichloromethane @ BP Solvent 
3 Isopropyl alcohol @ IP Solvent 
4 Glycerine  IP Plasticizer 
*   Quantity to be taken based on 100 % Assay and 0 % Loss on drying. 
$      Quantity of Griseofulvin has to be compensated with additional quantity, if process loss 
occurs during Micronisation in Fluid energy mill. 
*** Actual quantity of Maize starch to be taken per lot = 12.360 Kg – additional quantity of 
drug taken to get 100 % Assay and 0 % Moisture content. 
*** LOD compensation 
@ Does not contribute to the final mass of the product. 
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4.2 DRUG PROFILE 
 
4.2.1. GRISEOFULVIN 40, 41  
Structure: 
 
 
 
 
 
Chemical name: Griseofulvin is (1S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methylbenzofuran-2-
spiro-1- cyclohex-2'-ene-3,4'-dione 
 
Formula    : C17H17ClO6 
 
Molecular weight   : 352.8 
 
Description:  
A white to yellowish white powder, the particles of which are generally upto 5 μm in 
maximum dimension, although larger particles, which may occasionally exceed 30 μm may 
be present; almost odourless. 
 
Melting point    : 217oC-224 oC 
 
Solubility 
Freely soluble in dimethylformamide and in 1, 1, 2, 2-tetrachloroethane; soluble in acetone 
and in chloroform; slightly soluble in ethanol (95 per cent) and in methanol; practically 
insoluble in water. (Refer- Indian Pharmacopeia, volume I, pg 151, 2.4.26.Solubility of 
Griseofulvin)  
 
Category    : Antifungal 
Griseofulvin is fungistatic in vitro for various species of the dermatophytes Microsporum, 
Epidermophyton, and Trichophyton. The drug has no effect on bacteria or on other fungi. 
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Mechanism of Action 42 
A prominent morphological manifestation of the action of Griseofulvin is the production of 
multinucleate cells as the drug inhibits fungal mitosis. In mammalian cells treated with high 
concentrations, Griseofulvin causes disruption of the mitotic spindle by interacting with 
polymerized microtubules. The binding sites of Griseofulvin on the microtubular protein are 
distinct. In addition to its binding to tubulin, Griseofulvin also may bind to a microtubule-
associated protein. 
 
4.2.2. PHARMACOKINETIC DATA 43 
 
Absorption 
The absorption of Griseofulvin from the gastrointestinal tract is variable and incomplete. On 
average less than 50% of the oral dose is absorbed, but administration after a fatty meal and a 
reduction in particle size will increase the rate and extent of absorption. Following oral 
administration there is a phase of rapid absorption, and there after a phase of slower 
prolonged absorption. Griseofulvin exhibits linear pharmacokinetics. 
 
Distribution 
The volume of distribution is about 0.7 L/Kg and the Griseofulvin is ca 80% bound to plasma 
proteins predominantly serum albumin. Griseofulvin crosses placental barrier and may be 
excreted in breast milk. There is selective deposition of Griseofulvin in newly formed keratin 
in hair, skin and nails, which gradually moves to the surfaces of these appendages. 
 
Metabolism 
Griseofulvin undergoes metabolism to inactive metabolites, principally 6-
desmethylgriseofulvin or its glucoronide conjugate. 
 
Excretion 
The terminal half life ranges from 9.5 – 21 hours, with considerable intersubject variability. 
The majority of dose, principally as 6-desmethylgriseofulvin or as glucoronide conjugate are 
excreted in urine. With less than 1% administered dose being excreted as unchanged 
Griseofulvin. The reminder of the dose principally as metabolites, excreted in bile and faeces.  
  
Therapeutic uses 
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Mycotic disease of the skin, hair, and nails due to Microsporum, Trichophyton, or 
Epidermophyton responds to Griseofulvin therapy. Infections that are readily treatable with 
this agent include infections of the hair (tinea capitis) caused by Microsporum canis, 
Microsporum audouinii, Trichophyton schoenleinii, and Trichophyton verrucosum; 
"ringworm" of the glabrous skin; tinea cruris and tinea corporis caused by M. canis, 
Trichophyton rubrum, T. verrucosum, and Epidermophyton floccosum; and tinea of the hands 
(T. rubrum and T. mentagrophytes) and beard (Trichophyton species). Griseofulvin also is 
highly effective in "athlete's foot" or epidermophytosis involving the skin and nails, the 
vesicular form of which is most commonly due to T. mentagrophytes and the hyperkeratotic 
type to T. rubrum. Since very high doses of Griseofulvin are carcinogenic and teratogenic in 
laboratory animals, the drug should not be used systemically to treat trivial infections that 
respond to topical therapy. 
 
Untoward effects 
The incidence of serious reactions associated with the use of griseofulvin is very low. One of 
the minor effects is headache. Other nervous system manifestations include peripheral 
neuritis, lethargy, mental confusion, impairment of performance of routine tasks, fatigue, 
syncope, vertigo, blurred vision, transient macular edema, and augmentation of the effects of 
alcohol. Among the side effects involving the alimentary tract are nausea, vomiting, diarrhea, 
heartburn, flatulence, dry mouth, and angular stomatitis. Hepatotoxicity also has been 
observed. Hematologic effects include leukopenia, neutropenia, punctate basophilia, and 
monocytosis are observed.  
 
Contra indications 
Hepatic disease and porphyria. 
 
Storage  
To be stored in a tightly closed container. 
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4.3. RATIONALE FOR SELECTION OF CRITICAL STEPS AND ITS PROCESS 
PARAMETERS FOR VALIDATION 
 
4.3.1. DRY MIXING 
 
The dry-mixing step involves mixing of active ingredients with other additives using Rapid 
Mixer Granulator (RMG). Sieve Analysis, Water Content, Tapped Density for the Dry mix 
pool sample has to be done. The content uniformity of active ingredient Griseofulvin has to 
be established after 5 minutes during dry mixing process. The mixing of the active ingredient 
depends on the mixing time and speed of RMG, which affect the uniform distribution of drug 
during mixing. These critical steps are to be validated during the Dry mixing process. 
 
4.3.2. GRANULATION 
 
The granulation step involves converting the powder into free flowing near spherical granular 
mass. The amount of granulation solution added, mixing speed and time are critical variables. 
These variables affect the 
a) Granule strength(fines) 
b) Bulk density of blend  
c) Flow characteristics of granules 
These in turn affects the quality attributes of tablets like weight variation, Hardness, 
Disintegration Time and Dissolution.  
 
4.3.3. DRYING 
 
The drying step involves drying of wet mass. Moisture content in granules is important 
factor. If moisture content is more in granules it will lead to poor flow and poor hardness. If 
moisture content is less it will lead to capping, high friability and chipping. During drying the 
desire LOD will be maintained in the granules which will influence the quality parameters 
like tablet hardness, flow properties of granules, physical properties during compression. 
Drying of granules in fluid bed equipment (FBE) controls the moisture content. Inlet 
temperature of FBD is most critical variable for the same. Moisture content is checked 
periodically to establish the same. During the drying process the following variables are to be 
studied. 
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1. Inlet temperature (o C) 
2. Outlet temperature (o C) 
3. Product temperature (o C) 
4. Loss on Drying (% w/w) 
 
4.3.4. BLENDING 
 
This step involves mixing of granules with other blending material. The purpose of blending 
is to get a uniform distribution of Griseofulvin IP. This is followed by mixing of the blend 
with Magnesium stearate and Talc (Lubrication) to get good flow and anti-adhesion property 
of the blend. Mixing speed and time are critical variables in this process. Mixing time is 
critical as under blending will result in non uniform distribution of drug and poor flow, 
whereas over blending will result in de-mixing leading to non uniform distribution of drug 
and increases in disintegration time. Proper blending is established by checking Content 
uniformity & RSD (relative standard deviation) of drug at all the time intervals (After 20, 
25 & 30 min as per protocol) In addition to this, the following tests are to be done. They shall 
be carried out on final time interval samples only. 
a) Moisture content 
b) Sieve analysis 
c) Bulk density 
d) True density 
e) Compressibility index 
f) Assay 
 
4.3.5. COMPRESSION 
 
This step involves conversion of blended material into tablets as per specifications. The 
following are the variables considered for study during compression process. 
1. Thickness 
2. Speed of machine (10 - 20 RPM) 
3. Hopper fill (Full, Middle & Near end) 
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Following parameters were considered to establish the above-mentioned variables at 
regular intervals 
a) Dissolution values at different Thickness 
b) Appearance 
c) Group weight  
d) Individual weight variation 
e) Hardness 
f) Friability 
g) Disintegration  
h) Thickness 
i) Dissolution at different speeds (Griseofulvin IP) 
j) Uniformity of content at different speeds (Griseofulvin IP) 
k) Assay at different speeds (Griseofulvin IP) 
 
4.3.6. COATING 
 
The coating step involves the covering of tablet surface with a polymer film. In coating 
process pan RPM, temperature, spray rate, gun to bed distance and air pressure are critical 
process variables. These parameters affect the coating and final appearance of the tablets. 
Coating process is performed as per the instructions given in BMR. During the coating 
process, the initial weight of core tablets and final weight of coated tablets after coating are 
noted. Parameters to be considered for uniform coating of tablets are: 
 
a) Pan RPM: If the RPM of coating pan is not within the specified limit then uneven 
distribution of the coating solution on tablet takes place. 
b) Inlet/Exhaust temperature: If the temperature of coating pan is not within the 
specified limit then the drying will be insufficient which results twining and sticking 
of tablets or rough surface and cracking of the film. 
c) Spray rate: If the spray rate is not proper then the coating will not be uniform. 
d) Gun to be distance: If gun to be distance is not adequate, it results in rough surface 
or over wetting during coating. 
e) Air pressure: If the compressed air pressure (Main and atomization) is not adequate, 
it results in peeling or rough surface of tablets. 
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4.3.7. BLISTER PACKING 
This process involves packing of tablets in polythene lined aluminum foil and PVC blister 
pack. Temperature of rollers (sealing and forming) & speed of machine are critical variables. 
Adequate sealing roller temperature is essential to get proper sealing. Adequate forming 
roller temperature is essential to get proper blister formation. Less temperature will lead to 
leakage and higher of machine affects the following parameters. 
a) Proper sealing of blister pack 
b) Proper forming of blister pockets 
c) Configuration of blister pack 
 
Leak test and physical evaluation are the tests to be done to establish the above variables 
during blister packing operation. 
 
4.3.8. STABILITY STUDIES 
The purpose of the stability study is to establish, based on testing a minimum of three batches 
of the drug substance and evaluating the stability information (including, as appropriate, 
results of the physical, chemical, biological, and microbiological tests), a re-test period 
applicable to all future batches of the drug substance manufactured under similar 
circumstances. The degree of variability of individual batches affects the confidence that a 
future production batch will remain within specification throughout the assigned re-test 
period. Any evaluation should cover not only the assay, but also the levels of degradation 
products and other appropriate attributes. 
 
4.3.9. AREA MONITORING 
The air present in the process areas is tested by the Setting Plate Technique and the microbial 
content present in the air was found to be within the specified limits. 
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4.4. FLOW CHART FOR PROCESS VALIDATION  
4.4.1. GRANULATION STAGE 
EQUIPMENT PROCESS         PROCESS TESTS PERFORMED 
          VARIABLES 
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4.4.2. COMPRESSION STAGE 
EQUIPMENT PROCESS  PROCESS      TESTS PERFORMED 
              VARIABLES 
 
 
 
 
 
     Fig.2 
 
4.4.3. FILM COATING STAGE 
EQUIPMENT PROCESS  PROCESS      TESTS PERFORMED 
              VARIABLES 
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4.5 CRITICAL STEPS, VARIABLES TO BE STUDIED, MEASURED RESPONSE & 
ACCEPTANCE CRITERIA 
TABLE: NO. 6 
Stage Process 
variables 
Time Tests performed Acceptance criteria 
Dry 
mixing 
Mixing time 5 minutes Uniformity of content 100±15 % RSD NMT 6.0 % 
Bulk density, moisture 
content, sieve analysis 
For information 
 
TABLE: NO. 7 
Stage Process variables Time Tests 
performed 
Acceptance criteria 
Granulation Mixing time impeller 
reading during 
mixing 
As per BMR 
 
TABLE: NO. 8 
Stage Process variables Time Tests performed Acceptance 
criteria 
Drying Inlet & outlet temperature 
drying time 
Final 
drying 
Loss on drying/moisture 
content 
< 1.0 % w/w 
 
TABLE: NO. 9 
Stage Process 
variables 
Time Tests performed Acceptance criteria 
Blending Blending 
time 
20 &25 
minutes (20+5 
min) 
Uniformity of content & 
RSD 
 
 
100±15 % RSD NMT 6.0 % 
  
 
 
 
30 
minutes(25+5) 
Uniformity of content & 
RSD 
Assay, Moisture content, 
Compressibility Bulk 
density, sieve analysis & 
compressibility index 
 
 
As per the current In process 
specification 
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TABLE: NO. 10 
Stage Process 
variables 
Time Tests performed Acceptance criteria 
 
C
om
pr
es
sio
n 
Pre 
compression 
studies 
Optimum 
speed 
Dissolution at lower & 
higher thickness 
As per current finished product 
specification 
Machine 
speed  
(10 - 20 rpm) 
At different 
speeds 
Appearance  White capsule shaped, uncoated 
tablets, plain on both sides 
Group weight variation 12.800g ± 2.0 % 
(12.540 g ± 13.060 g) 
Individual weight 
variation 
640 mg ± 4%( 614.00 mg – 
666.00 mg) 
Thickness 4.70 mm ± 0.2 mm 
( 4.50 mm – 4.90 mm) 
Hardness NLT 3.0 kg/cm2 
Friability NMT 1.0 % w/w 
Disintegration time NMT 20 minutes 
Dissolution  NLT 80 % of Griseofulvin in 45 
minutes 
Content uniformity 85 – 115 % of label claim 
Hopper study 
at maximum 
speed 
Full hopper, 
middle of 
hopper & 
near end of 
hopper at 
optimum 
speed 
Individual weight 
variation 
640 mg ± 4% 9( 614.0 – 666.0 
mg) 
Thickness 4.70 ± 0.2 mm (4.50 – 4.90 
mm) 
Hardness NLT 3.0 kg/cm2 
Friability NMT 1.0 % w/w 
Disintegration time NMT 15 minutes 
Content uniformity 100 – 15 % of label claim 
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TABLE: NO. 11 
Stage Process 
variables 
Time Tests 
performed 
Acceptance criteria 
Coating Inlet temp. 
Exhaust temp. 
Pan speed 
atomization 
pressure spray 
rate gun 
distance 
Weight build up As per current finished 
product specification At the end of 
coating 
LOD 
Dissolution 
profile at 5,15, 
20, 
30&45minutes 
For information 
 
TABLE: NO. 12 
Stage Process 
variables 
Time Tests 
performed 
Acceptance criteria 
Blister 
packing 
Machine speed, 
forming and 
sealing 
temperature 
Blister appearance and quality, leak 
test and impurity 
As per sop 
 
YIELD DETAILS 
Record the yield at every stage as mentioned below. 
Blending, Compression, Coating, Inspection and Packing 
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4.6. LIST OF EQUIPMENTS USED IN VALIDATION STUDY OF GRISEOFULVIN 
TABLETS 
TABLE: NO. 13  
S.No 
Equipment used in Quality 
Control 
Intended Use 
1 HPLC(Aligant technology) Impurities and Related substances 
2 UV Identification of compounds 
3 IR Identification of functional groups 
4 GC Qualitative & Quantitative Analysis 
5 Muffle furnace Purity of the compound (Ash Value) 
6 Dissolution Apparatus Drug release from the dosage form 
7 Disintegration Time 
To determine the time of Disintegration of 
tablets 
8 WHT Weight, Hardness, Thickness Tester 
9 Melting Point Apparatus 
Calculate the melting point of the given raw 
material 
10 
Bulk and true Density 
apparatus 
To ensure the particle size/granules size 
11 Sieve shaker 
To calculate the percentage retains of raw 
materials 
12 Karl fisher apparatus Calculate the moisture content 
13 Sonicator To remove the dissolved gases/Uniform mixing 
14 Hot air oven Drying 
15 Ultra filtration (0.45µm) Preparation of HPLC mobile phase 
16 Electronic/Analytical balance To weigh accurate quantity of substances 
17 Ph To check the pH of the given solution 
 
TABLE: NO. 14 
S.No 
Equipment used in 
Granulation 
Intended Use 
1 Sifter 
To attain uniform sized powder 
particles/granules 
2 Rapid Mixing Granulator For Dry mixing and granulation 
3 Fluid Bed Granulator To achieve desired LOD of granules 
4 Binder agent preparation vessel Preparation of binding agent 
5 LOD analyser To check the LOD of the granules 
6 Multi mill Size reduction of Lumps 
8 Octagonal blender Blending of granules 
9 Weighing Balance Weighing the granules after blending 
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TABLE: NO. 15 
S.No 
Equipment used in 
Compression 
Intended Use 
1 Compression machine To compress the granules in to tablets 
2 Analytical balance To check the group weight of tablets 
3 Friabilator 
To assess the effect of friction & shock  
(Tablet Strength) 
4 WHT 
To check the Weight, Hardness & Thickness of 
each tablet 
5 Vernier To check the thickness of each tablet 
 
TABLE: NO. 16 
S.No Equipment used in IPQA Intended Use 
1 Analytical balance 
To check the group weight and individual weight 
variation of tablets 
2 Friabilator 
To assess the effect of friction & shock 
(Tablet Strength) 
3 WHT 
To check the Weight, Hardness & Thickness of 
each tablet 
4 Disintegration Time To determine the time of Disintegration of tablets
 
TABLE: NO. 17 
S.No Equipment used in Coating Intended Use 
1 Neocota Used for coating the uncoated tablets 
2 CSP tank & Stirrer Polymer solution preparation 
3 Colloidal mill Pigment solution preparation 
4 Agitator Mixing of both Polymer and Pigment solution 
 
TABLE: NO. 18 
S.No Equipment used in Packing Intended Use 
1 Blister Packing machine Primary Packing of the tablets 
2 Leak test To check the efficiency of the primary packing 
 
All the Equipments used in the manufacturing of Griseofulvin tablets have been tested for 
1. Installation qualification 
2. Operational qualification and 
3. Performance qualification 
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4.7. GENERAL TESTS FOR RAW MATERIALS 
 
1. DESCRIPTION: 
Colour, odour and physical state of the sample is identified by physical observation. 
2. SOLUBILITY: 
Soluble/Insoluble in specific solvents can be determined by the solubility test. 
3. IDENTIFICATION: 
The purity of raw material can be determined by Identification test. Various samples are 
identified by the various instruments like U.V., I.R., T.L.C., H.P.L.C., G.C., etc. In U.V and 
I.R sample absorbance is compared with standard absorbance. In T.L.C., sample Rf values are 
compared with the standard Rf value. 
4. PH TEST: 
Acidic/Basic/Neutral character of the substance can be determined by pH meter. 
5. SPECIFIC OPTICAL ROTATION: 
Optical rotation of the sample can be known by polari meter 
6. IMPURITIES AND RELATED SUBSTANCES PRESENT: 
Maximum, total amount of impurities and related substances present in the sample can be 
determined using HPLC method. 
7. HEAVY METAL TEST (in PPM): 
Heavy metals like As, Sb, Bi, Hg, Pb etc are present in the sample can be determined by this 
test.  
8. SULPHATED ASH TEST (in PPM): 
Amount of inorganic compounds present in the sample can be determined by this test. 
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9. MOISTURE TEST: 
If drug contains highly moisture, it’s function may be destroyed. Manufacturing process 
depends upon the moisture of raw materials. 
Procedure: 
Take the suitable quantity of anhydrous methanol in titration vessel and pour the accurate 
quantity of sample in it and titrate with K.F. reagent. 
% of water = V × F × 100/Wt 
Here V = Volume of Karl Fisher Reagent consumed for the sample titration. 
F = Factor of Karl Fisher Reagent. 
Wt = Weight of the sample in mg. 
10. BULK DENSITY/TRUE DENSITY TEST: 
The strength of the finished product depends upon the bulk density. 
Procedure: 
Mechanically tap the cylinder 500 times initially and measure the tapped volume (Vµ). 
Repeat the tapping an additional 750 times and measure the tapped volume (Vf). 
Calculation: 
Untapped density (Bulk Density)  =  W
V μ  grams/c.c 
Tapped density (True Density)  =  
f
W
V
 grams/c.c  
W  = Weight of the substance taken in grams 
Vµ  = Apparent volume obtained in ml. 
Vf  = Tapped final volume obtained in ml. 
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11. ASSAY: 
Quantity of drug present in the sample can be determined by this test. Different methods like 
UV, IR, HPLC etc. are used to determine the assay. 
12. FINENESS:  
The granulation process depends upon the fineness of the raw materials. 
Procedure: 
Weigh the sample and transfer in to sieve and after sieving the retains are collected and 
weighed. 
13. SIEVE ANALYSIS:  
All the sieves arranged in such a way that sieves with smaller number (#16) should be present 
on the top and larger number (#200) at the bottom. Weigh about 10-15 gm of the material to 
be analyzed and transfer it over the vertically arranged sieves. Then they are places over sieve 
analyzer for a specified period of time. Later they are analyzed for the percentage of material 
retained on each sieve by collecting the materials separately and weighing. 
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4.8.GENERAL TESTS TO BE PERFORMED FOR PACKING MATERIAL 
 
4.8.1. Aluminium foil 
TABLE: NO. 19 
 S.No Tests Performed 
1 Appearance 
2 Width 
3 Thickness of aluminium foil 
4 Aluminium foil Grammage 
5 HSL(heat seal lacquer) coating Grammage 
6 Printing 
7 Pin holes/m2 
8 Cello tape test 
9 Shade 
10 
Other details( role shall be free from dust, foreign matter, rough edge, 
scratches, core damages) 
11 AQL for defects 
 
4.8.2. PVC clear film 
TABLE: NO. 20 
S.No  Tests Performed 
1 Appearance 
2 Colour 
3 Width 
4 Thickness of PVC clear film 
5 Grammage 
6 
Other details( role shall be free from dust, foreign matter, rough 
edge, scratches, core damages) 
7 AQL for defects 
 
 
 
 
CHAPTER 4  MATERIALS AND METHODS 
 
DEPARTMENT OF PHARMACEUTICS, S.B.COLLEGE OF PHARMACY Page 42 
4.8.3. Carton 
TABLE: NO. 21 
S.No Tests Performed 
1 Appearance 
2 Internal Dimensions: length
3 Internal dimensions: width 
4 Internal dimensions: height 
5 Grammage 
6 Shade 
7 AQL for defects 
 
4.8.4. Sticker Hologram 
TABLE: NO. 22 
S.No  Tests Performed 
1 Appearance 
2 Dimensions - Length and width 
3 Grammage of film and adhesive 
4 
Performance(should not tear without leaving hologram metallization on 
application to substrate after 30 min curing time) 
5 
General details(tackiness, appearance without wrinkles, easy to peel off 
from the release paper, uniform adhesive coating) 
6 AQL for defects 
 
4.8.5. Shipper 
TABLE: NO. 23 
 S.No Tests Performed 
1 Appearance 
2 Grammage of each ply 
3 Thickness 
4 Internal Dimensions: length 
5 Internal Dimensions: Width 
6 Internal Dimensions: Height
7 LOD 
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4.9.METHODOLOGY 
MANUFACTURING AND SAMPLING PROCEDURES AT DIFFERENT 
STAGES OF PROCESS VALIDATION 
 
4.9.1. SAMPLING PROCEDURE AT DIFFERENT STAGES 
Three sets of samples were collected for content uniformity. One set of samples was used for 
analysis and the remaining two sets were kept as reserve sample.  
4.9.2. DRY MIXING 
The dry-mixing step was done for mixing of active ingredient with other additives in Rapid 
Mixer Granulator (RMG).The Content uniformity of Griseofulvin (API) was established at 
the end of 5 minutes during the validation of dry mixing process. The samples were 
withdrawn from 10 locations of the RMG as directed in the protocol (refer Fig) 
The acceptance criterion for the content uniformity of Griseofulvin is 100 ± 10% of the 
theoretical quantity, whereas the limit for relative standard deviation (RSD) should be NMT 
6.0%. The sample quantity is shall be between 448.857 gm to 1346.571 mg. Sampling was 
done with sampling rod. Samples were collected in tarred vials. 
 
 
 
            Top Layer 
 
         Bottom Layer 
 
 Side View        Top View 
    Fig.4 Rapid Mixer Granulator Sampling Locations 
 
       1 & 6 
 
4 & 9       5 & 10        2 & 7 
      
                    3 & 8 
 
1  2  5  3  4 
 
6  7  10  8  9 
CHAPTER 4  MATERIALS AND METHODS 
 
DEPARTMENT OF PHARMACEUTICS, S.B.COLLEGE OF PHARMACY Page 44 
4.9.3. GRANULATION 
The granulation was performed using RMG. The granulation step involves converting the 
powder in to wet dough mass. The granulation strength, bulk density of blend, dissolution, 
hardness of tablets etc are influenced by mixing time. Aqueous binding solution is used for 
granulation. The granulation end point is a critical process and the end point of granulation is 
determined by physical observation and Amperage reading of Impeller to correlate the 
granulation end point. 
4.9.4. DRYING: 
Moisture in granules or blend is important factor. If moisture content is more in granules it 
will lead to poor flow and Hardness. If moisture is less it will lead to capping, High friability 
and chipping. Drying of granules if, FBD controls the moisture content. Inlet temperature of 
FBD is most critical variable for the same. Moisture content is checked periodically to 
establish the same. The process of drying was carried out as per the batch manufacturing 
record at an inlet temperature of 40 oC – 50 oC till the moisture content comes to less than 
1% w/w. Then the outlet temperature to correlate the moisture content. Samples were 
withdrawn from five different places of the FBD bowl after drying and moisture content was 
checked. 
 
Fig.5. Sampling Locations for FBD after Drying of Granules 
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4.9.5. BLENDING: 
Sifted materials and sized granules were loaded into the Octagonal blender except 
Magnesium stearate and talc. Blender was started in inch mode to check for any leakage of 
material. On ensuring that there is no leakage, the material was blended for 20 & 25 minutes 
and samples were collected from 10 locations as shown in the figure below. Magnesium 
stearate and talc were mixed with equal quantity of blend taken from blender after 25 minutes 
of initial blending time. They are added to the remaining blend material in blender and 
blending process is performed for 5 minutes and 10 samples were collected using sampling 
rod at the sampling locations mentioned in the diagram. Samples were collected in tarred 
vials and analyzed for the following tests: 
1. Content uniformity & RSD 
2. Sieve analysis 
3. Bulk density 
4. True density 
5. Compressibility index 
6. Assay 
7. Moisture Content 
 
  Top Layer      Middle Layer 
 
        
 
 
 
 
       Bottom Layer 
Fig.6. Sampling Locations for Blender after Blending 
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4.9.6. COMPRESSION 
 
Compression was carried as per the Batch manufacturing record (BMR) with 8.5 mm × 16.5 
mm shallow concave capsule shaped punches and dies and by setting the machine at different 
speed of 10-20 RPM and following parameters were checked.  
Number of stations: 37 
Type of tooling: ‘D’ type 
 
PHYSICAL PARAMETERS TO BE CHECKED DURING COMPRESSION 
TABLE: NO. 24 
S.No Parameters Standard 
No. of Tablets 
taken for testing 
1 Appearance 
White capsule shaped, uncoated 
tablets, plain on both sides 
20 tablets 
2 
Weight of 20 tablets 
(group weight) 
12.800 ± 2%  
(12.540 - 13.060 g) 
20 tablets 
3 Hardness NLT 3.0 kg/cm² 6 tablets 
4 Thickness 
4.70 mm ± 0.2 mm 
( 4.50 mm – 4.90 mm) 
20 tablets 
5 Friability NMT 1.0 % w/w 20 tablets 
6 Disintegration time NMT 15 minutes 6 tablets 
7 
Individual weight 
variation 
640 mg ± 4%( 614.00 mg – 666.00 
mg) 
20 tablets 
8 
Group weight 
variation 
12.800g ± 2.0 % 
(12.540 g ± 13.060 g) 
20 tablets 
 
1. Compression machine was set at lower and high thickness and samples were collected 
for dissolution. 
2. After sampling, compression was carried out at optimum thickness. 
3. Compression machine at three different speeds between 10 – 30 RPM (15, 20 & 25 
RPM) of turret and samples were collected for Dissolution and Content uniformity 
testing at each speed. Also physical parameters at each speed were done. 
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4.9.7. HOPPER STUDY 
To evaluate the effect of vibration during compression on blend uniformity, hopper study was 
carried out at maximum speed of the machine. Filling the hopper completely and 
compression machine was run. Tablets were collected when powder level in the hopper is 
full, approximately middle of the hopper and when it is near the end of the hopper. The 
collected samples were tested for uniformity of content and physical parameters. 
4.9.8. COATING 
Coating was carried as per BMR. Before starting coating, average weight of core tablets was 
recorded. After coating process the appearance and weight gain during coating was tested. 
After completion of coating check for Description, Weight variation of 20 tablets, LOD and 
Weight buildup. 
4.9.8.1. CONDITIONS TO BE FULFILLED DURING COATING PROCESS 
1. After loading the pan with tablets, it is rotated for 1 minute for dedusting and pre 
heating of tablets. 
2. Inlet air temperature: 50 - 60  oC 
3. Outlet air temperature: 45 - 50 oC 
4. Atomization air pressure: 3.0 - 5.0  kg/cm2 
5. Pan RPM: 2 - 3 
6. Spray gun distance: 20 - 26 cm 
7. Spray rate: 40 - 60  ml/gun/min 
                                      
 
 
      
 
 
 
  
 
  
 
 Fig.7 Sampling Locations for Coating Pan 
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4.9.8.2. DISSOLUTION PROFILE 
Dissolution was carried out after compression, coating and for finished product. The samples 
are taken from the pooled samples.  
Specifications for Dissolution 
• Apparatus  : IP – I 
• RPM   : 100 
• Medium  : 900 ml of a 4.0 per cent w/v solution of sodium lauryl  
     sulphate(Degassed) 
• Temperature  : 37oC ± 0.5oC 
• Sample Size  : 6 Tablets 
• Absorbance  : 291 nm 
• Time interval  : 60 minutes 
• Limit   : NLT 70 % of stated amount 
 
4.9.9. PACKING 
Packing of Griseofulvin  tablets include both primary and secondary packing. Blister packing 
is the primary packing and the process of primary packing involves the following steps: 
 Forming, Feeding, Sealing, Printing, Punching/Cutting. 
4.9.9.1. Blister Packing 
Packing was done as per Batch Packing Record. Before starting packing operations, the 
sealing roller temperature and forming roller temperature and speed of the machine were 
checked. After packing, blister quality, blister appearance, proper sealing, leak test and 
impurities were tested. The process of secondary packing involves checking the blisters, 
Counting, Cartoning, Stickering, Carton weighing, Shippering, and shipper weighing. 
4.9.10. STABILITY STUDIES 
A drug substance should be evaluated under storage conditions (should be sufficient to cover 
storage, shipment, and subsequent use). The long term testing should cover a minimum of 12 
month’s duration for at least three primary batches at the time of submission and should be 
continued for a period of time sufficient to cover the proposed re-test period. 
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Intended storage conditions as per ICH guidelines 
TABLE: NO. 25 
Study Storage condition Minimum time period covered by 
data at submission 
Long term* 
25°C ± 2°C/60% RH ± 5% RH 
or 
30°C ± 2°C/65% RH ± 5% RH 
12 months 
Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months  
 
*It is up to the applicant to decide whether long term stability studies are performed at 25 ± 
2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH. 
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5. RESULTS 
 
5.1. RESULTS FOR EQUPMENT QUALIFICATION  
 
Observation 
 
All the equipments have been tested for their Installation, Operational and Performance 
Qualification. The results were present within the specified IH limits.  
 
Conclusion 
 
Based on the report, validation of the Instrument qualification was concluded to be 
successful. The qualified equipments were used for the manufacturing of Griseofulvin tablets. 
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5.2. RESULTS FOR RAW MATERIALS 
 
TABLE: NO. 26    
 
Griseofulvin (IP)
S.No 
Test 
Performed IP Specifications PVG01 PVG02 PVG03 
1 Appearance white powder complies complies complies 
2 Solubility 
Freely soluble in dimethyl 
formamide and in 1,1,2,2-
tetrachloroethane; soluble in 
acetone and in chloroform; 
slightly soluble in ethanol (95 
per cent) and in methanol; 
practically insoluble in water. complies complies complies 
3 Identification  
4 I)IR   Method A complies complies complies 
  
II)Chemical 
test Method B  complies complies complies 
5 
 Melting 
point 217 - 224 oC 218.4 oC 218.0 oC 218.2 oC
6 
appearance 
of solution 
Test solution not more intensely 
coloured than reference solution complies complies complies 
7 Acidity 
Not more than 1.0 ml of  0.2M 
NaOH is required to change 
the colour of test solution. complies complies complies 
8 
specific 
optical 
rotation +352° to +364° 361o 362 o 363 o 
9 
Related 
substances 
(dechloro 
Griseofulvin, 
dehydro 
Griseofulvin) 
Detected by GC 
 complies complies complies 
10 heavy metals NMT 20 ppm 
 < 20 
ppm 
 < 20 
ppm 
 < 20 
ppm 
11 
matter 
soluble in 
light 
petroleum NMT 0.2 % 0.2% 0.1% 0.2% 
12 
sulphated 
ash NMT 0.2 % 0.1% 0.1% 0.05% 
13 LOD NMT 1.0 % 0.1% 0.1% 0.08% 
14 Assay NLT 97.0 % and NMT 102.0 % 
98.8 
%w/w 
99.4 
%w/w 
100.1 
%w/w 
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TABLE: NO. 27 
Povidone IP 
S.No Test 
Performed 
IP Specification PVG01 PVG02 PVG03 
1 Appearance White hygroscopic powder complies complies complies 
2 Solubility Freely soluble in water, in chloroform 
and in ethanol 95%.  practically 
insoluble in ether 
complies complies complies 
3 Odour Odourless complies complies complies 
4 Identification 
   I)IR  Test A complies complies complies 
  II)Chemical test Test D complies complies complies 
5 Clarity and 
colour of 
solution 
Solution A is clear, not more intensely 
coloured than reference solution 
complies complies complies 
6 Heavy metals NMT 10 ppm complies complies complies 
7 Aldehydes NMT 9.1 ml of 0.1M NaOH complies complies complies 
8 Vinyl 
pyrrolidone 
NMT 3.6 ml of 0.05M Iodine complies complies complies 
9 Sulphated ash NMT 0.1% 0.05% 100.05% 200.05% 
10 Water NMT 5.0% 4.1 
%w/w 
4.1 
%w/w 
4.1 
%w/w 
 
TABLE: NO. 28 
Sodium lauryl sulphate 
S.No Test Performed IP Specification PVG01 PVG02 PVG03 
1 Appearance white powder complies complies complies 
2 Solubility 
Freely soluble in water, 
forming an opalescent 
solution; partly soluble in 
ethanol (95%). complies complies complies 
3 Identification tests 
  I)Foam test  Test A complies complies complies 
  II) Chemical test Test B & C complies complies complies 
  III)Sodium salts Test D complies complies complies 
4 Alkalinity NMT 0.5 ml of 0.1M HCl complies complies complies 
5 
Non-Esterified 
alcohols NMT 4% 0.30% 0.30% 0.30% 
6 
Sodium chloride and 
sodium sulphate NMT 8.0% 4.00% 4.00% 4.00% 
7 Assay NLT 85.0 % 98.7 %w/w 98.7 %w/w 98.7 %w/w 
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TABLE: NO. 29 
Hypromellose USP 
S.No Test Performed   PVG01 PVG02 PVG03 
1 Appearance  
 white 
fibrous 
powder 
white fibrous 
powder 
white fibrous 
powder 
white fibrous 
powder 
2 identification         
I)chemical test 
 Method 
A, B, C complies complies complies 
3 viscosity   5.8 cps 5.7 cps 5.7 cps 
4 LOD 
 NMT 
5.0 % 2.20% 3.30% 3.30%
5 residue on ignition 
 NMT 
1.5 %  0.50% 0.50% 0.50% 
6 heavy metals 
 NMT 20 
ppm complies complies complies 
7 assay( Methoxy content)  28-30 % 28.30% 28.30% 28.30% 
8 
assay (Hydroxypropoxy 
content)  7-12 % 9.10% 8.90% 8.90% 
9 particle size   100 100 100 
10 pH  5-8 7.1 7.29 7.29 
11 chlorides 
 NMT 
0.5 % < 0.5 % < 0.5 % < 0.5 % 
 
TABLE: NO. 30 
Dichloromethane 
S.No Test Performed BP Specification PVG01 PVG02 PVG03 
1 appearance 
A clear, colourless, volatile 
liquid complies complies complies 
2 solubility 
Sparingly soluble in water, 
miscible with ethanol(96%). complies complies complies 
3 identification  
  I)IR 
Sample spectrum compared 
with standard complies complies complies 
  
 II)Refractive 
index 1.423 – 1.425 1.423 1.423 1.423 
4 acidity 
NMT 0.15 ml of 0.1M 
NaOH 0.1 ml 0.1 ml 0.1 ml 
5 relative density 1.320 – 1.332 1.323 1.323 1.323 
6 heavy metals NMT 1.0 ppm  complies complies complies 
7 free chlorine 
No blue colour with KI and 
Starch complies complies complies 
8 
residue on 
evaporation  NMT 1.0 g 0.1 mg 0.1 mg 0.1 mg 
9 water NMT 0.05 %m/m 0.006%m/m 0.006%m/m 0.006%m/m
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TABLE: NO. 31 
Isopropyl alcohol 
S.No 
Test 
Performed IP Specification PVG01 PVG02 PVG03 
1 appearance clear colourless liquid complies complies complies 
2 odour characteristic and spirituous complies complies complies 
3 solubility 
Miscible with water, with chloroform and 
with ether. complies complies complies 
4 Identification test 
  
I)chemical 
test Test A complies complies complies 
  
II)chemical 
test Test B complies complies complies 
5 
acidity or 
alkalinity NMT 0.06 ml of 0.1M NaOH  complies complies complies 
6 
distillation 
range Not less than 95.0% v/v 97.40% 97.40% 97.40% 
7 
refractive 
index Between 1.377 and 1.378 1.377 1.377 1.377 
8 weight/ml Between 0.782 and 0.786 g 
0.783 
g/ml 
0.783 
g/ml 
0.783 
g/ml 
9 
Aldehydes 
and ketones NMT 2.0 ml of 0.1M NaOH complies complies complies 
10 
benzene and 
related 
substances Determined by GC 
NOT 
DETEC
TED 
NOT 
DETEC
TED 
NOT 
DETEC
TED 
11 
non volatile 
matter Not more than 0.002% w/v 
0.0006 
%w/v 
0.0006 
%w/v 
0.0006 
%w/v 
12 
water 
insoluble 
matter 
Mix 1 volume with 19 volumes of water; 
no opalescence is produced. complies complies complies 
13 water      Not more than 0.50% w/w 
0.07 
%w/w 
0.07 
%w/w 
0.07 
%w/w 
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TABLE: NO. 32 
Glycerin IP 
S.No 
Test 
Performed IP Specification PVG01 PVG02 PVG03 
1 appearance  
Clear colourless, odourless, syrupy 
liquid Complies complies complies
2 Identification 
  I)IR    complies complies complies
  
 II)Refractive 
index Test A 1.472 2.472 3.472 
3 water content Not more than 2.0% w/w 
0.3 
%w/w 
0.3 
%w/w 
0.3 
%w/w 
4 assay NLT 98.0 % and NMT 101.0 % 
99.6 % 
w/w 
99.6 % 
w/w 
99.6 % 
w/w 
 
TABLE: NO. 33 
Colloidal silicone dioxide IP 
S.No Batch No IP SPECIFICATIONS PVG01 PVG02 PVG03 
1 Appearance 
light, fine , White, 
Amorphous powder Complies Complies Complies
2 Solubility 
Practically insoluble in water 
and in mineral acids with the 
exception of hydrofluoric 
acid. Dissolves in hot 
solutions of alkali hydroxides. 
When 1 g is shaken 
vigorously with 20 ml of 
carbon tetrachloride for 3 
minutes; a transparent gel is 
produced. complies complies complies 
3 Identification  
  I)Test for Silicates 
Gives the reaction for 
Silicates complies complies complies 
4 pH 3.5 – 5.5 4.2 4.6 4.2 
5 chlorides NMT 250 ppm complies complies complies 
6 arsenic NMT 8 ppm complies complies complies 
7 Heavy metals NMT 25 ppm complies complies complies 
8 loss on ignition NMT 5.0 % 2.20% 2.30% 2.20% 
9 Assay 
NLT 99.0 % and NMT 100.5 
% 100.00% 99.90% 100.00% 
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TABLE: NO. 34 
Starch IP 
S.No Batch No IP SPECIFICATIONS PVG01 PVG02 PVG03 
1 Appearance 
Very fine, white or slightly 
yellowish powder which are 
readily reducible to powder, 
creaks when pressed between the 
fingers complies complies complies 
2 Odour Odourless complies complies complies 
3 Solubility 
Practically insoluble in cold water 
and in ethanol (95%) complies complies complies 
4 Identification 
  
I)Microscopy 
II)Chemical 
test Method A & B complies complies complies 
5 Acidity NMT 2.0 ml complies complies complies 
6 Iron NMT 40 ppm complies complies complies 
7 Florescence No fluorescence complies complies complies 
8 
Oxidizing 
substances 
no distinct brown or blue colour is 
observed. complies complies complies 
  
Microbial 
limits        
  
I)Total 
aerobic count NMT 10 cfu/g 
 < 10 
CFU/G 
 < 10 
CFU/G 
 < 10 
CFU/G 
9 
II)Pathogens  
E.coli & 
Salmonella  Negative Absent Absent Absent 
10 Sulphated ash NMT 0.6 % 0.06% 0.06% 0.06% 
11 
Loss on 
drying NMT 15 % w/w 
7.1  
% w/w 
7.1  
% w/w 
7.1  
% w/w 
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TABLE: NO. 35 
Sodium starch glycollate IP 
S.No Batch No IP SPECIFICATIONS PVG01 PVG02 PVG03 
1 Appearance 
Very fine, white or off-
white, free-flowing powder Complies 
Complie
s Complies 
2 Solubility 
Practically insoluble in 
water; insoluble in most 
organic solvents Complies complies complies 
3 Odour Odourless Complies complies complies 
4 Identification 
  I) IR   Method A Complies complies complies 
  
II) Chemical test 
( Iodine) Method B Complies complies complies 
  
III) Chemical 
test ( for 
Sodium) Method C Complies complies complies 
5 pH 5.5 – 7.5 6.146 6.146 6.146 
6 heavy metals NMT 20 ppm  < 20 ppm 
  
< 20 
ppm 
 < 20 
ppm 
7 iron NMT 20 ppm  < 20 ppm 
 
< 20 
ppm 
 < 20 
ppm 
8 sodium chloride  NMT 10.0 % 5.6% 5.6% 5.6% 
10 microbial contamination  
  
I)total bacterial 
count  NMT 10 cgu/g 
 < 10 
CFU/G 
 < 10 
CFU/G 
 < 10 
CFU/G 
  
II) pathogens  
E.coli & 
Salmonella Negative Absent Absent Absent 
11 LOD NMT 10.0 % 
7.5  
 % w/w 
7.5  
% w/w 
7.5  
% w/w 
12 Assay 
NLT 2.8 % - NMT 4.5 % of 
Na 3.70% 3.70% 3.70% 
13 Bulk density IH 0.72 g/ml 
0.72 
g/ml 0.72 g/ml 
14 True density IH 0.91 g/ml 
0.91 
g/ml 0.91 g/ml 
15 
Finess % 
retained on #200 IH 0% 0% 0% 
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TABLE: NO. 36 
Magnesium stearate IP 
S.No Batch No IP SPECIFICATIONS PVG01 PVG02 PVG03 
1 Appearance 
Very fine, light, white 
powder; unctuous and 
free from grittiness. Complies Complies Complies 
2 Solubility 
Practically insoluble in 
water, in ethanol and in 
ether Complies complies complies 
3 Odour odourless complies complies complies 
4 Identification 
  I)Freezing point    NLT 53 oC 56 oC 56 oC 56 oC 
5 
Appearance of 
solution 
Test solution not more 
intensely coloured than 
reference solution complies complies complies 
6 
Appearance of 
solution of fatty 
acids 
Test solution not more 
intensely coloured than 
reference solution complies complies complies 
7 
Acidity and 
alkalinity 
NMT 0.05 ml of 0.1 M 
HCl or 0.1 M NaOH is 
required to change the 
colour of the solution. complies complies complies 
8 
Acid value of fatty 
acids 195-210 200 200 200 
9 Free stearic acid NMT 3.0 % 1.40% 1.40% 1.40% 
10 Zinc stearate 
no violet precipitate is 
formed. complies complies complies 
11 Heavy metals NMT 20 ppm < 20 ppm < 20 ppm < 20 ppm 
12 Chlorides  NMT 250 ppm 
< 250 
ppm 
< 250 
ppm 
< 250 
ppm 
13 sulphates NMT 0.6 % < 0.6 % < 0.6 % < 0.6 % 
14 LOD  6.0 % 4.5 %w/w 4.5 %w/w 4.5 %w/w
15 Assay 
NLT 3.8 % and NMT 
5.0 % 4.6 %w/w 4.6 %w/w 4.6 %w/w
16 Microbial limits        
  
i) Total aerobic 
microbial count NMT 10 cfu/g 
< 10 
CFU/G 
< 10 
CFU/G 
< 10 
CFU/G 
  
ii)pathogens(E.coli,
salmonella,P.Aerugi
nosa,S.aureus) Negative Absent Absent Absent 
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TABLE: NO. 37 
Talc IP 
S.No Batch No IP SPECIFICATIONS PVG01 PVG02 PVG03 
1 
Appearance 
A white or almost white powder, 
free from grittiness; readily 
adheres to the skin; unctuous to 
the touch; odourless. complies complies complies 
2 Solubility 
Practically insoluble in water 
and in dilute solutions of acids 
and alkali hydroxides complies complies complies 
3 Identification  
  I)microscopy  Method A complies complies complies 
  
II) Chemical 
test Method B complies complies complies 
  
III) Chemical 
test Method C complies complies complies 
4 
acidity/ 
alkalinity 
not more than 0.3 ml of 0.1M 
HCl complies complies complies 
5 iron NMT 10 ppm complies complies complies 
6 
acid soluble 
substances NMT 2.0 % 0.2% 0.7% 0.2% 
7 
water soluble 
substances NMT 10 mg 0.0001% 0.1000% 0.0001% 
8 carbonates No effervescence  complies complies complies 
9 chlorides NMT 250 ppm complies complies complies 
10 
organic 
compounds Residue NMT slightly yellow complies complies complies 
11 LOD NMT 1.0 % 
0.12 % 
w/w 
0.2 % 
w/w 
0.12 % 
w/w 
12 
Microbial 
limits  
  
I)Total viable 
aerobic count NMT 10 cfu/g
< 10 
CFU/G
< 10 
CFU/G 
< 10 
CFU/G
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TABLE: NO. 38 
Purified Water 
S.No Batch No IP SPECIFICATIONS PVG01 PVG02 PVG03 
1 appearance 
Clear, colourless liquid; odourless 
and tasteless. Complies complies complies 
2 
Acidity or 
Alkalinity 
 
Negative Complies complies complies 
3 Ammonium 
Water with alkaline potassium 
mercuric-iodide solution is not more 
intensely coloured than the standard 
solution 
Complies Complies Complies 
4 
Calcium and 
Magnesium 
A pale blue colour is produced with 
ammonia buffer, mordant black II 
and Disodium edetate 
Complies Complies Complies 
5 Heavy metals (NMT 0.1 ppm) complies complies complies 
6 Chloride 
The appearance of the solution not 
changed for 15 minutes  Complies Complies Complies 
7 Nitrate  (NMT 0.2 ppm) complies complies complies 
8 Sulphate 
The appearance of the solution not 
changed for one hour
Complies Complies Complies 
9 
Oxidisable 
substances 
The solution remained faintly pink 
Complies Complies Complies 
10 
Residue on 
evaporation 
NMT 0.001 % 
 0.0002% 0.0002% 0.0002% 
11 pH (5 – 7) 6.27 6.17 6.31 
12 Ammonia 
Yellow colour produced immediately 
is not darker than that of standard 
solution 
Complies Complies Complies 
13 CO2 The mixture remained clear Complies Complies Complies 
15 
Total 
Microbial 
Count Negative 
complies complies complies 
16 
Test for 
pathogens Negative complies complies complies 
17 
Microbial 
Limit  (NMT 100 cfu/ml) complies complies complies 
Observation 
All the raw materials have been tested for their purity and Quality as per the specifications 
and the results were present within the specified IP limits and USP limits for Hypromellose, 
BP specifications for Dichloromethane  
Conclusion 
Based on the report, we can conclude the validation of Raw materials used in the 
manufacturing of Griseofulvin tablets as successful. 
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5.3. RESULTS FOR PROCESS VALIDATION 
 
5.3.1. DRY MIXING 
 
Fixed Parameters 
RMG speed                                                                 : Slow 
Lot size                                                                       : 120.96 
Variables considered for study                                      : Mixing time 
Time interval studied                                                   : 5 minutes 
Measured response                                                      : Content uniformity and RSD 
Acceptance criteria                                                      : 100 ± 15 % (RSD NMT 6.0%) 
Batch taken for study                                                   : GRIS01, GRIS02, GRIS03. 
 
5.3.1.1. The Content Uniformity and RSD values after 5 minutes of dry mixing 
TABLE: NO. 39 
Dry mixing time 5 Minutes 
Batch No GRIS01 GRIS02 GRIS03 
Minimum  94.03 93.33 94.18 
Maximum 98.12 100.23 99.18 
Average 96.13 95.89 96.24 
RSD 1.38 2.24 1.94 
 
Observations: 
It is observed from the compiled analytical data of the content uniformity and it’s RSD after 5 
minutes dry mix the values of the three batches are well within the acceptance criteria as per 
IH specifications. The distribution of Griseofulvin IP is well acceptable at 5 minutes of dry 
mixing as shown by the samples analyzed data. The results show closer homogeneity of drug 
distribution in the dry mix stage. 
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5.3.1.2. Dry mix pooled sample results of B. No GRIS01, GRIS02, GRIS03. 
TABLE: NO. 40   
S.No Parameter GRIS01 GRIS02 GRIS03 
1 % retains on #100 0.0% w/w 0.0% w/w 0.0% w/w 
2 Tapped density( g/ml) 0.446 0.435 0.426 
3 Water Content (%w/w) 1.87 1.94 1.86 
 
Observations: 
 
Sieve analysis, water content and tapped density values of three batches are comparable and 
are in closer homogeneity as per IH specifications. 
 
Conclusion: 
 
The dry mixing time of 5 minutes is concluded as validated mixing time at fast speed. 
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5.3.2. GRANULATION 
Fixed parameters 
  Lot size                                                    : 120.96 kg (dry basis)  
  Variables considered for study                   : Mixing time, Impeller reading, Chopper     
            amperage.   
Acceptance criteria                                     : Physical appearance granules 
Measured response                                     : Impeller reading, Chopper amperage 
Batch taken for study                                 : GRIS01, GRIS02, GRIS03. 
 
5.3.2.1. Impeller reading of RMG 
TABLE: NO. 41 
Lot No Final reading of Impeller (Ampere) 
I 1.8 
II 2.0 
III 1.9 
 
Observations: 
The above compilation data shows that uniform granules formation of all three batches was 
observed at the Impeller (Slow speed) amperage 1.8 – 2.0 amps as per BMR (IH 
specifications). 
 
Conclusion: 
The desired granular mass was obtained between impeller amperage 1.8-2.0 amps. Resultant 
granules after drying and milling have desired flow properties. All the three batches resulted 
in granules with desired flow and compaction, which is evident from data of compression 
tablets. Hence the granules stage of Griseofulvin 375 tablet is concluded as validated at 
impeller amperage of 1.8-2.0 amps. 
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5.3.3. DRYING 
Fixed parameters  
Lot size                                                   : 120.96kg 
Variables considered for study                  : Drying time and Drying temperature 
Measured response                                  : LOD (loss on drying) 
Acceptance criteria                                  : < 1.0 %w/w 
Batches taken for study                            : GRIS01 (Lot-I, Lot-II, Lot-III) 
 
5.3.3.1. Inlet, Outlet, Product Temperatures and LOD Results 
TABLE: NO. 42 
Batch no 
Inlet 
temperature 
(oC) 
Outlet 
temperature 
(oC) 
Product 
temperature 
(oC) 
LOD  
(% w/w) 
VB001 48 23 23 0.81 
VB002 48 23 23 0.82 
VB003 47 22 21 0.79 
 
Observation: 
 
Drying was carried out as per BMR (IH specifications). During drying the desired LOD of  
< 1.0 % w/w was achieved at air drying for 8-25 minutes. 
 
Conclusion: 
 
According to observations during drying for all three batches, it was concluded that only air 
drying the granular material after granulation is required till the LOD is NMT 1.0%. 
 
 
 
 
 
 
 
 
 
CHAPTER 5                            RESULTS 
DEPARTMENT OF PHARMACEUTICS, S.B.COLLEGE OF PHARMACY Page 65 
 
5.3.4. BLENDING 
Fixed parameters                         
   Blender RPM                                      : Slow speed 
   Blender Load                                      : 537.6kg 
Variables considered for study                : Blending time 
Time interval studied                             : After 20, 25 & 30 (25+5) minutes 
 Measured response                               : Uniformity of content and RSD 
Acceptance criteria                                : 100 ± 15 %( RSD NMT 6.0%) 
Batches taken for study                          : GRIS01, GRIS02, GRIS03 
 
5.3.4.1. The Content Uniformity of Griseofulvin and RSD values after blending 
TABLE: NO. 43 Batch No: GRIS01 
Blending time (Minutes) 20 25 30 
Minimum  89.57 90.78 89.53 
Maximum 102.41 98.48 99.5 
Average 95.86 95.00 92.46 
RSD 3.79 2.55 3.58 
 
TABLE: NO. 44 Batch No: GRIS02 
Blending time (Minutes) 20 25 30 
Minimum  88.08 94.14 93.49 
Maximum 98.72 100 100.39 
Average 93.23 96.92 96.04 
RSD 3.73 1.73 2.51 
 
 
TABLE: NO. 45 Batch No: GRIS03 
Blending time (Minutes) 20 25 30 
Minimum  89.94 89.9 87.22 
Maximum 99.29 98.29 100.29 
Average 94.4 93.79 95.16 
RSD 3.1 2.77 3.68 
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Observations 
It is observed from the compiled analytical data of the uniformity of content and it is RSD in 
the blend that the values of all the three batches are well within the acceptance criteria as per 
IH specifications, when blended for 20 & 25 minutes. The Content uniformity results of 
Griseofulvin in the blend of Griseofulvin tablets after blending of all the three batches of 
GRIS01, GRIS02, and GRIS03. 
 
5.3.4.2. Test Results for Blend 
TABLE: NO. 46 
S.No 
Test 
Performed GRIS01 GRIS02 GRIS03 
1 Appearance 
white granular 
powder 
white granular 
powder 
white granular 
powder 
2 Identification       
  I) IR  Complies complies complies 
  II)UV Complies complies complies 
  
III)Chemical 
test Complies complies complies 
3 Assay 375.5 mg 375.5 mg 375.5 mg 
4 Water content 1.90% 101.90% 201.90% 
5 Bulk density 0.83 g/ml 0.84 g/ml 0.85 g/ml 
 
Observation 
The distribution of Griseofulvin IP is well acceptable at 25 minutes of blending and 5 
minutes lubrication as shown by the samples analyzes. The results show closer homogeneity 
of drug distribution in the blend as per IH specifications. 
5.3.4.3. Blend pooled sample results 
TABLE: NO. 47  
Parameters 
Batch no 
GRIS01 GRIS02 GRIS03
Sieve analysis (% w/w) 
% retains on # 20 33.40 18.90 41.10 
% retains on # 40 68.00 67.30 77.30 
% retains on # 60 78.20 82.70 82.90 
% retains on # 80 82.50 85.70 85.10 
% retains on # 100 85.80 87.20 87.70 
Untapped density (g/ml) 0.76 0.74 0.73 
Tapped density (g/ml) 0.86 0.87 0.85 
Moisture content 2.28 2.15 1.50 
CHAPTER 5                            RESULTS 
DEPARTMENT OF PHARMACEUTICS, S.B.COLLEGE OF PHARMACY Page 67 
 
 
Observation 
Sieve analysis, untapped density, Tapped density and Moisture content results for the blend 
pooled samples were found to be within limits as per IH. 
 
5.3.4.4. The Assay results of Blend as follows 
TABLE: NO. 48  
Batch no GRIS01 GRIS02 GRIS03
Assay (mg) of 
Griseofulvin 98.47 99.86 98.66 
 
Observation 
 
Assay values of all three batches are comparable and are in closer homogeneity as per IH 
specifications. 
 
Conclusion 
 
The blending time of 30 minutes is concluded as validated blending time at slow speed of 
blender for Griseofulvin 375 blending, when the process is performed in 2000 litres capacity 
Octagonal blender for a batch size of 537.6 kg. 
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5.3.5. COMPRESSION 
Fixed parameter 
Number of station                              : 37 stations 
Variables considered for study                    : Thickness, Compression speed, Hopper level 
Speeds studied                                             : 10–20 RPM 
Batches taken for study                                : GRIS01, GRIS02, GRIS03 
 
5.3.5.1. Response and Acceptance criteria during compression 
TABLE: NO. 49  
MEASURED RESPONSE ACCEPTANCE CRITERIA 
Appearance  
White capsule shaped, uncoated tablets plain on 
both sides 
Group weight variation 12.80 g ± 2% (12.540 - 13.060g) 
Individual weight variation 640.00mg ± 4% (614.00mg - 666.00mg) 
Thickness 4.70 ± 0.2mm (4.50 to 4.90mm) 
Hardness NLT 3.0 kg/cm² 
Friability NMT 1.0% w/w 
Disintegration time NMT 20 minutes 
 
5.3.5.2.Dissolution values at different thickness 
Limit: NLT 80 % in 45 Minutes 
TABLE: NO. 50  
% of Griseofulvin 
Batch No  GRIS 01 GRIS 02 GRIS 03 
Thickness Lower Higher Lower Higher Lower Higher 
Minimum 90.42 90.47 86.62 90.18 90.38 93.66 
Maximum 97.46 98.83 89.61 94.79 98.33 102.58 
Average 92.71 93.45 87.83 93.16 94.54 96.59 
 
Observation: Dissolution of tablets compressed at lower and higher thickness complies with 
IH specification. 
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5.3.5.3. Physical parameters of tablets compressed at different speeds of 10, 15 and 20 
RPM for three batches (GRIS01, GRIS02 and GRIS03) 
TABLE: NO. 51    
Batch No: GRIS01 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Parameter Specification 10RPM 15RPM 20RPM 
1 Appearance 
white capsule shaped, 
uncoated tablets, plain on 
both sides 
Complies Complies Complies 
2 
Group weight of 
20 tablets 
12.800 ± 2%  
(12.540 - 13.060 g) 
12.788 - 
12.826 
12.782 - 
12.816 
12.792 - 
12.852 
3 
Individual 
weight 
variation(mg) 
640.0mg ± 4% 
(614.0 - 666.0mg) 
625 - 655 628 - 656 629 – 659 
4 
Hardness 
(Kg/cm²) 
NLT 3.0 Kg/cm² 
8.25 - 
10.36 
8.90 - 
10.50 
9.20 - 
10.62 
5 Thickness (mm) 
4.70  ± 0.2mm 
(4.50 - 4.90mm) 
4.65 - 4.79 4.65 - 4.81 4.65 - 4.80 
6 
Friability 
(%w/w) 
NMT 1.0% 0.14 - 0.19 0.09 - 0.20 0.11 - 0.20 
7 
Disintegration 
time 
NMT 20 minutes 9.22 - 9.45 9.24 - 9.38 9.28 - 9.38 
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TABLE: NO. 52 Batch No: GRIS02 
 
S.No Parameter Specification 10RPM 15RPM 20RPM 
1 Appearance 
white capsule shaped, 
uncoated tablets, 
plain on both sides 
Complies Complies Complies 
2 
Group weight 
of 20 tablets 
12.800 ± 2% 
 (12.540 - 13.060 g) 
12.805- 
12.825 
12.803 - 
12.835 
12.805 - 
12.836 
3 
Individual 
weight 
variation(mg) 
640.0mg ± 4% 
(614.0 - 666.0mg) 
629 - 660 630 - 660 629 - 662 
4 
Hardness 
(Kg/cm²) 
NLT 3.0 Kg/cm² 9.20 - 12.68 9.50 - 12.55 9.86 - 12.96 
5 
Thickness 
(mm) 
4.70  ± 0.2mm 
(4.50 - 4.90mm) 
4.60 - 4.81 4.62 - 4.78 4.65 - 4.78 
6 
Friability 
(%w/w) 
NMT 1.0% 0.17 - 0.26 0.13 - 0.20 0.13 - 0.20 
7 
Disintegration 
time 
NMT 20 minutes 9.10 - 9.25 
10.18 - 
10.58 
10.08 - 
10.38 
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TABLE: NO. 53 Batch No: GRIS03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Parameter Specification 10RPM 15RPM 20RPM 
1 Appearance 
white capsule shaped, 
uncoated tablets, plain 
on both sides 
Complies Complies Complies 
2 
Group weight 
of 20 tablets 
12.800 ± 2%  
(12.540 - 13.060 g) 
12.798 - 
12.820 
12.798 - 
12.855 
12.806 - 
12.856 
3 
Individual 
weight 
variation(mg) 
640.0mg ± 4% 
(614.0 - 666.0mg) 
628 - 660 630 - 660 630 – 662 
4 
Hardness 
(Kg/cm²) 
NLT 3.0 Kg/cm² 
10.11 - 
13.12 
10.98 – 
12.88 
10.20 - 
12.45 
5 
Thickness 
(mm) 
4.70  ± 0.2mm 
(4.50 - 4.90mm) 
4.65 - 4.78 4.64 - 4.80 4.64 - 4.78 
6 
Friability 
(%w/w) 
NMT 1.0% 0.13 - 0.16 0.17 - 0.20 0.17 - 0.20 
7 
Disintegration 
time 
NMT 20 minutes 
10.18 – 
10.24 
10.18 – 
10.28 
9.22 – 9.58 
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5.3.5.4. Dissolution of Griseofulvin tablets at different speeds for three batches 
Limit: NLT 80 % in 45 Minutes 
TABLE: NO. 54 Batch No: GRIS01 
RPM 10 15 20 
Minimum 93.11 90.09 91.86 
Maximum 97.93 94.31 95.26 
Average 96.13 92.70 93.66 
 
TABLE: NO. 55 Batch No: GRIS02 
RPM 10 15 20 
Minimum 95.64 98.07 98.35 
Maximum 102.03 103.08 101.44 
Average 99.42 99.99 100.30 
 
TABLE: NO. 56 Batch No: GRIS03 
RPM 10 15 20 
Minimum 90.84 90.39 91.86 
Maximum 100.19 96.28 95.53 
Average 94.88 93.24 93.74 
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5.3.5.5. Uniformity of content and RSD values of Griseofulvin  in compressed tablets at 
different speeds for three batches. 
TABLE: NO. 57 Batch No: GRIS01 
RPM 10 15 20 
Minimum 101.82 98.93 95.66 
Maximum 105.62 110.86 107.64 
Average 103.42 104.61 101.64 
RSD 1.12 4.05 5.37 
 
TABLE: NO. 58 Batch No: GRIS02 
RPM 10 15 20 
Minimum 94.47 97.39 97.08 
Maximum 100.29 103.92 101.09 
Average 98.03 101.61 99.83 
RSD 1.84 1.67 1.09 
 
TABLE: NO. 59 Batch No: GRIS03 
RPM 10 15 20 
Minimum 98.08 97.18 92.09 
Maximum 106.67 101.62 98.95 
Average 100.82 99.32 95.16 
RSD 2.42 1.52 2.73 
 
5.3.5.6. Assay values of Griseofulvin tablets at different speeds for three batches. 
TABLE: NO. 60 
Batch No GRIS01 GRIS02 GRIS03 
Griseofulvin IP 101.38 101.11 101.77 
 
Observation:  
 All physical parameters, Dissolution, Uniformity of content and Assay of pool tablet values 
of Griseofulvin compressed tablets at different speeds are well within the limits and are 
complying with IH specification. 
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5.3.5.7. Physical parameters of Griseofulvin  tablets compressed at different hopper 
levels for three batches  
TABLE: NO. 61  
Batch No GRIS01 
S.No parameter Specification FULL MIDDLE 
NEAR 
END 
1 
Individual weight 
variation(mg) 
640.0mg ± 4% 
(614.0 - 666.0mg) 
627 - 656 629 - 659 628 – 662 
2 Thickness (mm) 
4.70  ± 0.2mm 
(4.50 - 4.90mm) 
4.65 - 4.80 4.65 - 4.80 4.62 - 4.79 
3 Hardness (Kg/cm²) NLT 3.0 Kg/cm² 9.58 - 10.12 9.65 – 9.75 9.58 - 10.21 
4 Friability(%w/w) NMT 1.0% 0.11 0.11 0.11 
5 Disintegration time NMT 20 minutes 9.28 9.36 9.32 
 
TABLE: NO. 62  
Batch No: GRIS02 
S.No parameter Specification FULL MIDDLE 
NEAR 
END 
1 
Individual weight 
variation(mg) 
640.0mg ± 4% 
(614.0 - 666.0mg) 
628 - 660 628 - 662 624 - 660 
2 Thickness (mm) 
4.70  ± 0.2mm 
(4.50 - 4.90mm) 
4.62 - 4.76 4.62 - 4.77 4.62 - 4.78 
3 Hardness (Kg/cm²) NLT 3.0 Kg/cm² 
11.30 - 
12.66 
11.55 - 
12.96 
10.58 - 
12.82 
4 Friability(%w/w) NMT 1.0% 0.17 0.18 0.14 
5 Disintegration time NMT 20 minutes 9.36 9.32 9.35 
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TABLE: NO. 63 
 Batch No: GRIS03 
S.No parameter Specification FULL MIDDLE 
NEAR 
END 
1 
Individual weight 
variation(mg) 
640.0mg ± 4% 
(614.0 - 666.0mg) 
630 - 662 630 - 660 628 – 662 
2 Thickness (mm) 
4.70  ± 0.2mm 
(4.50 - 4.90mm) 
4.64 - 4.78 4.65 - 4.78 4.65 - 4.78 
3 Hardness (Kg/cm²) NLT 3.0 Kg/cm² 
10.20 - 
11.86 
10.25 - 
11.86 
09.58 - 
11.75 
4 Friability(%w/w) NMT 1.0% 0.20 0.18 0.19 
5 Disintegration time NMT 20 minutes 9.32 9.48 9.42 
 
 
5.3.5.8. Dissolution of Griseofulvin  in compressed tablets at different levels of hopper 
(Full, Middle, near end) for three batches. 
 
Limit: NLT 80 % in 45 Minutes 
TABLE: NO. 64 FULL HOPPER 
Batch No GRIS01 GRIS02 GRIS03
Minimum 95.65 97.49 90.77 
Maximum 98.79 101.20 94.67 
Average 97.47 99.41 92.98 
 
TABLE: NO. 65 MIDDLE HOPPER 
Batch No GRIS01 GRIS02 GRIS03
Minimum 91.38 92.99 92.32 
Maximum 99.35 101.12 97.16 
Average 94.10 96.20 94.79 
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TABLE: NO. 66 NEAR END HOPPER 
Batch No GRIS01 GRIS02 GRIS03
Minimum 90.68 93.27 92.30 
Maximum 98.87 96.77 96.05 
Average 95.16 94.56 94.17 
 
Observation: 
All physical parameters and dissolution values at different hopper level are well within the 
acceptance criteria and complying with the IH specification. 
 
5.3.5.9. Uniformity of content values of Griseofulvin tablets at different levels of hopper 
(Full, Middle, Near end) for three batches. 
TABLE: NO. 67 FULL HOPPER 
Batch No GRIS01 GRIS02 GRIS03
Minimum 95.38 96.39 93.30 
Maximum 101.40 102.25 99.38 
Average 98.36 100.24 95.73 
RSD 1.66 1.89 2.41 
 
TABLE: NO. 68 MIDDLE HOPPER 
Batch No GRIS01 GRIS02 GRIS03
Minimum 94.10 96.34 98.39 
Maximum 99.81 103.22 105.54 
Average 96.43 100.67 101.21 
RSD 1.92 2.42 2.3 
 
TABLE: NO. 69 NEAR END HOPPER 
Batch No GRIS01 GRIS02 GRIS03
Minimum 93.74 100.96 98.61 
Maximum 100.97 108.22 102.06 
Average 98.65 104.65 100.09 
RSD 2.02 2.45 1.22 
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Observation: 
 
All physical parameters and uniformity of content values at different hoper levels are well 
within the acceptance criteria and complying with the IH specification. 
 
Conclusion: 
 
According to the results observed, it was concluded that the compression process is validated 
and is under control for all the three batches of Griseofulvin tablets. 
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5.3.6. COATING 
Fixed parameters                          :  537.6 Kg 
Variables considered for study       :  Spray rate, Pan RPM, Peristaltic pump rate, Spray gun to 
               tablet bed distance, Atomizing air pressure, inlet  &  
               outlet temperature. 
Measured response          :  Dissolution profile and all tests as per current finished 
               product IH Specification. 
Acceptance criteria                      : As per current Finished product Specification. 
Batches taken for study                : GRIS01, GRIS02, GRIS03. 
 
5.3.6.1. Coating parameters for three batches  
TABLE: NO. 70 
S.No Parameter Standard 
Batch No 
GRIS01 GRIS02 GRIS03
1 Inlet temperature 50 - 60 oC 60 60 59 
2 Outlet temperature 45 - 50 oC 46 46 46 
3 Atomization pressure 3.0 - 5.0 Kg/cm2 3.0 5.0 5.0 
4 Pan RPM 2 - 3 3 3 3 
5 Spray gun distance (moving) 20 - 26 cm 23 24 23 
6 Spray rate 40 - 60 ml/gun/min 53 52 52 
7 Weight build up Theoretical 6.66mg 6.72 7.03 6.84 
   
 
5.3.6.2. Dissolution profile of Griseofulvin tablets for three batches Limit: NLT 70 % in 
60 Minutes 
TABLE: NO. 71 Batch No: GRIS01 
Time 
interval 
(Minutes) 
5 15 20 30 45 
Minimum 17.50  58.38  68.95  86.60  88.59  
Maximum  27.75  83.64  86.99  102.01  97.34 
Average  21.42  70.36  76.84  93.44  92.01 
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TABLE: NO. 72 Batch No: GRIS02 
Time 
interval 
(Minutes) 
5 15 20 30 45 
Minimum 31.15  77.13  89.26  92.21  96.73  
Maximum  53.09  90.31  97.47  97.79  108.30 
Average  38.47  85.44  92.18  95.07  99.33 
 
TABLE: NO. 73 Batch No: GRIS03 
Time 
interval 
(Minutes) 
5 15 20 30 45 
Minimum 22.18  72.22  84.17  89.31  92.23  
Maximum 59.21 87.33 92.58 97.09 98.64 
Average 37.81 82.21 89.84 91.72 94.15 
 
Observation 
 
Weight build up for all three batches observed was 1.08 to 2.50 mg per tablet. Dissolution 
profile of Griseofulvin tablets was observed within the specified IH limit. The coating 
process proved to be consistent among the batches. Therefore it was concluded that the 
coating process is validated. 
 
Conclusion 
 
According to the results observed, it was concluded that the compression process is validated 
and is under control for all the three batches of Griseofulvin tablets. 
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5.3.7. BLISTER PACKING 
Fixed parameters                      
                  Blister forming temperature       :   150 – 180oC 
                   Sealing temperature                       :   180 - 210oC 
Variables considered for study                           :   Speed of the machine 
Speeds studied                                                 :   30 – 40 cuts/minute 
Measured Response                                          :   Blister quality, Leak test 
Batches taken for study                                     :   GRIS01, GRIS02, GRIS03 
 
Observation: 
Blister packs comply with Leak test and Blister quality and were found to be satisfactory as 
per IH specifications at the speed of 30-40 cuts/minute and the specified forming and sealing 
temperatures.  
 
Conclusion 
At specified machine speed i.e. 25-40 cuts/minute and specified forming & sealing 
temperature, the blister packs formed comply with the specified limits mentioned in protocol 
and this speed is considered as validated. 
 
5.3.7.1 Microbial activity study in Griseofulvin tablets for three batches 
TABLE: NO. 74 
Batch No IH Specification GRIS01 GRIS02 GRIS03 
Total aerobic bacteria count  NMT 500 CFU/g 10 CFU/g < 10CFU/g < 10 CFU/g 
Total aerobic yeast count  NMT 50 CFU/g 10 CFU/g < 10CFU/g < 10 CFU/g 
Pathogens( P.aeruginosa, 
E.coli, S.aureus, Salmonella 
Shall be absent Absent Absent Absent 
 
Observation 
Microbial content of all three batches comply with the finished product specification. 
Conclusion 
From the above results obtained, it was concluded that the microbial activity was found to be 
absent. 
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5.3.1. YIELD RESULTS 
 
TABLE: NO. 75 
 
Stage 
Batch No 
GRIS01 GRIS02 GRIS03 
Blending 99.91 99.93 99.91 
Compression 98.29 98.22 97.72 
Coating 97.61 97.50 97.08 
Inspection 97.26 98.19 97.96 
Packing 98.34 98.98 98.30 
 
Conclusion 
 
From the above results, it was concluded that the yields for all the three batches is 
satisfactory and within the specified limits. 
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5.3.2. FINISHED PRODUCT 
 
TABLE: NO. 76 
S.No Test Performed 
IH 
SPECIFICATIONS GRIS01 GRIS02 GRIS03 
1 Appearance 
white to off-white film 
coated capsule shaped 
tablets 
complies  complies  complies 
2 Identification  
  i)IR  
IR spectrum of sample 
was compared with 
Griseofulvin RS complies complies complies 
  ii)chemical test As per IH specification complies complies complies 
3 Related substances 
Determined by GC as 
per IH specification complies complies complies 
4 Dissolution 
Limit: NLT 70 % in 60 
Minutes 96.37 98.92 98.76 
5 Uniformity of weight 
12.80 g ± 2% (12.540 - 
13.060g) complies complies Complies 
6 DT NMT 20 9 min 10 min 11 min 
7 Assay IH specification 373.8 mg 373.8 mg 373.8 mg 
8 Average  weight 
640.00mg ± 4% 
(614.00mg - 
666.00mg) 647.017 mg 647.017 mg 647.017 mg 
9 Thickness 
4.70 ± 0.2mm (4.50 to 
4.90mm) 4.58 mm 4.58 mm 4.58 mm 
10 Hardness NLT 3.0 kg/cm² 11.6 kg/cm2 11.6 kg/cm3 11.6 kg/cm4 
11 Water content IH specification 2.2 %w/w 2.2 %w/w 2.2 %w/w 
 
Conclusion:  
 
From the above results, we can conclude that the manufacturing process is in a state of 
control and capable of producing quality product uniformly. 
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5.4.1. STABILITY REPORT FOR ALL THE THREE BATCHES STUDIED UNDER SPECIFIED CONDITIONS 
TABLE: NO. 77 STABILITY REPORT FOR ALL THE THREE BATCHES STUDIED UNDER SPECIFIED CONDITIONS 
Stability Study- GRIS01 
Label Claim: Each film coated tablet contain Griseofulvin IP 
Storage conditions: 40 ± 2 oC / 75 % ± 5 % RH (Accelerated Stability Studies) 
Shelf life: 36 Months 
S.no Description Average Weight 
Disintegration 
time Hardness 
Water  
(% w/w) Dissolution 
Related 
substances Assay 
Microbial limits  
a.Bacteria  b.Fungi  
C.Pathogens 
Spec 
Write off white 
film coated 
capsule shaped 
tablets 
647.0 ± 
2.5%(630.
83 mg and 
663.18 
mg) NMT 30 min 
NLT 2.5 
kg/cm2 
NMT 6.0  
% w/w 
NLT 70% 
in 60 min complies 
NLT 
95% & 
NMT 
105% 
a.NMT 500 CFU/g  
b.NMT 50 CFU/g  
c.Shall be absent 
Stage Initial Complies 646.42 11 
10.04 - 
12.1 1.9 93.0 - 103.0  complies 99.4 complies 
1M Complies 649.13 9 
9.04 - 
11.39 2.4 
98.14 - 
102.12 complies 100.75 NA 
2M Complies 642.07 10 
10.80 - 
12.19 2.0 
94.89 - 
13.84 complies 100.04 NA 
3M Complies 643.36 10 
10.97 - 
12.76 1.6 
87.63 - 
91.62 complies 99.72 NA 
6M ON GOING STABILITY STUDY 
 
Observation: All the parameters are within the specified limits 
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TABLE: NO. 78 
Stability Study- GRIS01 
Label Claim: Each film coated tablet contain Griseofulvin IP 
Storage conditions: 25 ± 2 oC / 60 % ± 5 % RH (Long-term storage condition) 
Shelf life: 36 Months 
S.no Description Average Weight 
Disintegration 
time Hardness 
Water  
(% w/w) Dissolution 
Related 
substances Assay 
Microbial limits  
a.Bacteria  b.Fungi  
C.Pathogens 
Spec 
Write off 
white film 
coated capsule 
shaped tablets 
647.0 ± 
2.5%(630.83 
mg to 663.18 
mg) NMT 30 min 
NLT 2.5 
kg/cm2 
NMT 6.0  
% w/w 
NLT 70% 
in 60 min complies 
NLT 
95% & 
NMT 
105% 
a.NMT 500 CFU/g  
b.NMT 50 CFU/g  
c.Shall be absent 
Stage 
Initial Complies 646.42 11 
9.23 -
12.18 1.9 
93.00 – 
103.00 complies 99.4 complies 
3M Complies 648.875 11 
10.77 - 
11.59 2.5 
89.95 - 
94.81 complies 100.33 NA 
6 M 
ON GOING STABILITY STUDY 
9 M 
12 M 
18 M 
24 M 
36 M 
48 M 
 
Observation: All the parameters are within the specified limits 
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TABLE: NO. 79 
Stability Study- GRIS02 
Label Claim: Each film coated tablet contain Griseofulvin IP 
Storage conditions: 40 ± 2 oC / 75 % ± 5 % RH (Accelerated Stability Studies) 
Shelf life: 36 Months 
S.no Description Average Weight 
Disintegration 
time Hardness 
Water  
(% w/w) Dissolution 
Related 
substances Assay 
Microbial limits  
a.Bacteria  b.Fungi  
C.Pathogens 
Spec 
Write off white 
film coated capsule 
shaped tablets 
647.0 ± 
2.5%(630.83 
mg and 663.18 
mg) NMT 30 min 
NLT 2.5 
kg/cm2 
NMT 6.0 
% w/w 
NLT 70%  
in 60 min complies 
NLT 
95% & 
NMT 
105% 
a.NMT 500 CFU/g  
b.NMT 50 CFU/g  
c.Shall be absent 
Stage 
Initial Complies 641.11 12 
10.5 - 
111.23 2.3 94.8 complies 100.4 complies 
1M Complies 652.61 12
10.09 - 
11.11 1.8 96.72 complies 100.16 NA
2M Complies 639.63 10 
10.31 - 
11.34 1.7 99.53 complies 99.19 NA 
3M Complies 649.63 11 
6.08 - 
7.23 1.6 99.02 complies 101.54 NA 
6M ON GOING STABILITY STUDY 
 
Observation: All the parameters are within the specified limits 
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TABLE: NO. 80 
Stability Study- GRIS02 
Label Claim: Each film coated tablet contain Griseofulvin IP 
Storage conditions: 25 ± 2 oC / 60 % ± 5 % RH (Long-term storage condition) 
Shelf life: 36 Months 
S.no Description Average Weight 
Disintegrati
on time Hardness 
Water 
(% 
w/w) 
Dissolution Related substances Assay 
Microbial limits  
a.Bacteria  b.Fungi  
C.Pathogens 
Spec 
Write off 
white film 
coated capsule 
shaped tablets 
647.0 ± 
2.5%(630.83 
mg to 663.18 
mg) 
NMT 30 
min 
NLT 2.5 
kg/cm2 
NMT 
6.0 % 
w/w 
NLT 70% 
in 60 min complies 
NLT 
95% & 
NMT 
105% 
a.NMT 500 CFU/g  
b.NMT 50 CFU/g  
c.Shall be absent 
Stage 
Initial Complies 639.54 12 7.5 – 10.23 1.8 95.20 complies 99.20 complies 
3M Complies 653.875 12 6.68 - 7.28 2.6 95.89 complies 101.28 NA 
6 M 
ON GOING STABILITY STUDY 
9 M 
12 M 
18 M 
24 M 
36 M 
48 M 
 
Observation: All the parameters are within the specified limits 
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TABLE: NO. 81 
Stability Study- GRIS03 
Label Claim: Each film coated tablet contain Griseofulvin IP 
Storage conditions: 40 ± 2 oC / 75 % ± 5 % RH (Accelerated Stability Studies) 
Shelf life: 36 Months 
S.no Description Average Weight 
Disintegration 
time Hardness 
Water 
(%w/w) Dissolution 
Related 
substances Assay 
Microbial limits  
a.Bacteria  
b.Fungi  
C.Pathogens 
Spec 
Write off white 
film coated 
capsule shaped 
tablets 
647.0 ± 
2.5%(630.83 
mg and 663.18 
mg) NMT 30 min 
NLT 2.5 
kg/cm2 
NMT 
6.0 % 
w/w 
NLT 70% in 60 
min complies 
NLT 
95% & 
NMT 
105% 
a.NMT 500 
CFU/g  b.NMT 
50 CFU/g  
c.Shall be absent 
Stage 
Initial Complies 639.54 12 
7.5 – 
10.52 1.8 95.2 complies 99.2 complies 
1M Complies 642.24 12 
10.40 - 
11.56 2.3 98.31 complies 99.92 NA 
2M Complies 645.87 11 
10.80 - 
12.19 1.9 100.19 complies 100.13 NA 
3M Complies 648.97 13 
9.84 - 
10.19 2.5 98.88 complies 109.11 NA 
6M ON GOING STABILITY STUDY 
 
 
Observation: All the parameters are within the specified limits 
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TABLE: NO. 82 
Stability Study- GRIS03 
Label Claim: Each film coated tablet contain Griseofulvin IP 
Storage conditions: 25 ± 2 oC / 60 % ± 5 % RH (Long-term storage condition) 
Shelf life: 36 Months 
S.no Description Average Weight 
Disintegration 
time Hardness 
Water  
(% w/w) Dissolution 
Related 
substances Assay 
Microbial limits  
a.Bacteria  b.Fungi  
C.Pathogens 
Spec 
Write off white 
film coated 
capsule shaped 
tablets 
647.0 ± 
2.5%(630.83 
mg to 663.18 
mg) NMT 30 min 
NLT 2.5 
kg/cm2 
NMT 6.0 
% w/w 
NLT 70% 
in 60 min complies 
NLT 
95% 
& 
NMT 
105% 
a.NMT 500 CFU/g  
b.NMT 50 CFU/g  
c.Shall be absent 
Stage 
Initial Complies 639.54 12 
7.57 -
9.34 1.8 95.2 complies 99.2 complies 
3M Complies 653.875 12 
6.68 - 
7.28 2.6 95.89 complies 
101.2
8 NA 
6 M 
ON GOING STABILITY STUDY 
9 M 
12 M 
18 M 
24 M 
36 M 
48 M 
 
Observation: All the parameters are within the specified limits 
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6. DISCUSSION 
 
The process validation of Griseofulvin 375 mg tablets for the batches GRIS01, GRIS02, 
GRIS03 was conducted for a batch size of 0.84 million tablets at Dry mixing, Blending, 
Compression, Coating and Packing stage. 
 
DRY MIXING 
The distribution of Griseofulvin IP is well acceptable at 5 minutes of dry mixing as shown by 
the samples analyzed data. The results show closer homogeneity of drug distribution in the 
dry mix stage as per IH specification. Sieve analysis, water content and tapped density values 
of three batches for dry mix pooled samples are comparable and are in closer homogeneity. 
Hence dry mixing time of 5 minutes at slow speed is concluded as validated dry mixing time 
for Griseofulvin 375mg tablets. 
GRANULATION 
The above compilation data shows that uniform granules formation of all three batches was 
observed at the Impeller (Slow speed) amperage 1.8 – 2.0 amps. The desired granular mass 
was obtained between impeller amperage 1.8-2.0 amps. Resultant granules after drying and 
milling have shown desired flow properties. In all the three batches desired flow and 
compaction is well observed, which is evident from data of compressed tablets. Hence the 
granules stage of Griseofulvin 375 tablet is concluded as validated at impeller amperage of 
1.8-2.0 amps. 
DRYING 
Drying was carried out as per BMR (IH specification). During drying the desired LOD of < 
1.0 % w/w was achieved at air drying for 8-25 minutes. It was concluded that only air drying 
the granular material after granulation is required till the LOD is NMT 1.0%. Hence the 
drying time of 8-25 minutes is concluded as validated. 
BLENDING 
The blending time of 30 minutes is concluded as validated blending time at slow speed of 
blender for Griseofulvin 375 blending, when the process is performed in 2000 liters capacity 
Octagonal blender for a batch size of 537.6 kg. The distribution of Griseofulvin is well 
acceptable at 25 minutes of blending and 5 minutes lubrication as shown by the samples 
analyzes. The results show closer homogeneity of drug distribution in the blend. Particle size 
distribution, Bulk density & Tapped density and Assay values of all three batches are 
CHAPTER 6  DISCUSSION 
 
DEPARTMENT OF PHARMACEUTICS, S.B.COLLEGE OF PHARMACY Page 96 
comparable and are in closer homogeneity. Hence the blending time 30 minutes as mentioned 
in the BMR (IH specification) stands validated. 
COMPRESSION 
The compression for all the three has been validated for different compression speed on 37-
station compression machine. Entire compression was carried out in three different speeds. 
The physical parameters, results of dissolution and assay of the tablets compressed at 
different speeds of 10-20 RPM were well within the acceptable IH specified limits. The 
results are comparable among all the three runs. From the above it can be concluded that the 
Griseofulvin tablets of batch size 0.84 million tablets stands validated for compression speed 
range of 10-20 RPM on station compression machine. 
COATING 
The coating validated was performed for three consecutive batches. The weight buildup in 
tablets was measured and it is found within limits. It was concluded that the coating has to be 
performed with the parameters as mentioned in the BMR (IH specification) in order to obtain 
the desired buildup. The dissolution profile of all coated tablets of three batches is 
comparable. Finished product reports of all the three batches of GRIS01, GRIS02, and 
GRIS03 shows that final product meets the finished product specification. 
BLISTER PACKING 
At IH specified machine speed i.e. 25-40 cuts/minute and forming & sealing temperature, the 
blister packs formed comply with the specified IH limits for all the three batches of GRIS01, 
GRIS02, GRIS03 mentioned in protocol and this speed is considered as validated. 
FINISHED PRODUCT 
Finished product reports of all the three batches of GRIS01, GRIS02 & GRIS03 shows that 
final product meets the finished product IH specification. 
STABILITY REPORT 
The stability reports were present within the specified limits for all the three validation 
batches, GRIS01, GRIS02 & GRIS03 for long term and accelerated storage conditions. So 
the stability study was concluded to be validated. 
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7. SUMMARY AND CONCLUSION 
1. All the raw materials used in the manufacturing of Griseofulvin 375mg Tablets, 
were tested as per the given specifications and the results were within the limits. 
Hence the validation of raw materials was concluded. 
2. The equipment used in the manufacturing of the Griseofulvin 375mg Tablets were 
checked for their Installation, Operation and Performance Qualification and 
concluded. 
3. The dry mixing time of 5 minutes is concluded as validated mixing time at fast 
speed. 
4. The desired granular mass was obtained between impeller amperage 1.8-2.0 amps. 
Resultant granules after drying and milling have desired flow properties. All the 
three batches resulted in granules with desired flow and compaction, which is 
evident from data of compression tablets. Hence the granules stage of 
Griseofulvin 375 tablet is concluded as validated at impeller amperage of 1.8-2.0 
amps. 
5. According to observations during drying for all three batches, it was concluded 
that only air drying the granular material after granulation is required till the LOD 
is NMT 1.0%. 
6. The blending time of 30 minutes is concluded as validated blending time at slow 
speed of blender for Griseofulvin 375 blending, when the process is performed in 
2000 litres capacity Octagonal blender for a batch size of 537.6 kg. 
7. From the dissolution profile it was concluded that the compression process was 
validated. 
8. From the weight build up it was concluded that the validation of coating was 
concluded. 
9. From the finished product results it was concluded that the process validation of 
Griseofulvin 375mg Tablets was concluded. 
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8. SCOPE FOR FUTURE STUDIES 
1. Ongoing stability study (Accelerated and Long term) is to be carried out for the 
Griseofulvin 375mg Tablets. 
2. Any changes in the manufacturing formula, manufacturing process etc of Griseofulvin 
tablets may leads to revalidation of the same. 
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